

CURRICULUM VITAE

NAME : Gilles André Dominique SALLES

TITLES: M.D., Ph.D.

Professional Address:

Memorial Sloan Kettering Cancer Center
Koch Building
530 East 74th Street
10021 New York
Phone : 1 646 608 2642
Mail: sallesg@mskcc.org

New York State Board of Physician registration : 312234
NPI number : 1083389290

Training and Professional experience:

M.D degree, Université Claude Bernard Lyon-1 (1989)
Board specialization in Internal Medicine (1989),
Board specialization in Oncology (1992),
Ph.D. (Immunology) Université Claude Bernard Lyon-1 (1994)
- Resident in Lyon University hospitals (1984-1989)
- Research Fellow at the Dana Farber Cancer Institute, Harvard Medical School, Boston (1990-92)
- Assistant Professor at University Claude Bernard Lyon-1 (1992-95)
- Professor of Hematology, University Claude Bernard Lyon-1 (1996)

Present Functions and Responsibilities

Chief of the Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center - New-York, US
Professor of Medicine, Weill Cornell Medical College

Past Administrative Activities

Administrative Activity	Date
Chair of the Hematology Collegium of Academic in Hospices Civils de Lyon (Lyon University Hospital)	2001 – 2006
Member of the Board of Physicians of the Hospices Civils de Lyon (Lyon University Hospital)	2003 – 2015
Chair of the Research Committee of the Hospices Civils de Lyon (Lyon University Hospital)	2003 – 2011
Member of the selection committee for academic promotions in medicine – Université Claude Bernard Lyon-1	2004 – 2011 2017
Member of the Administrative Board of the Medical Faculty Lyon –Sud Charles Mérieux	2010 – 2014
Vice-President for Research of the Board of Directors of the Hospices Civils de Lyon (Lyon University Hospital)	2010 – 2016
Member of the Coordinating Committee for Biomedical Research and Public Health of the Hospices Civils de Lyon (Lyon University Hospital)	2007 – 2020
- Chair of the Committee	2007 - 2009 2013 – 2016
Member of the Strategic Council of the Fondation des Hospices Civils de Lyon (donation and charity promotion of the institution)	2013 - 2017
Member of the Strategic group for drug prescription of the Hospices Civils de Lyon (Lyon University Hospital)	2019 - 2020

RESEARCH SUPPORT

Completed programs as PI :

- * 2000 – 2002 National Hospital Program for Clinical Research (Ministry of Health, France) : FL2000 study (prospective phase III study for the treatment of follicular lymphoma) (200 k€)
- * 2008 - 2010: International Competitive Biomedicine Cluster – Lyon : ASPAREC : Development of a new recombinant L-asparaginase (585 k€)
- * 2008 - 2012: French National Cancer Institute : GOAL : Genomic and Outcome of Aggressive Lymphoma (550 k€)
- * 2013 – 2018: Roche Genentech: Integrated Genetic Analyses of FL patients treated in the PRIMA trial (500 k€)
- * 2011 – 2015; and renewed 2015 – 2019 : Institut Carnot CALYM : Consortium pour l'accélération de l'Innovation dans le Lymphome (Consortium to accelerate innovation in Lymphoma) ; French Ministry for Research and High Education ; amount variable but usually > 2000 k€/year ; PI and coordinator, 10% of effort.
- * 2015 – 2020: CLIP2 = Center for early phase clinical trials ; French National Cancer Institute (480 k€) for 4 years ; PI.
- * 2011 – 2020: Coordination of clinical research in Cancer in Lyon University Hospital (joint program with the Cancer center of Lyon Leon Berard) ; (500 K€/year) ; Principal Investigator Co-PI= Gilles Salles & David Perol
- * 2017 – 2021 : Ligue Nationale Contre le Cancer – 100k€/year – Antigen receptors signaling and metabolism in lymphoma ; PI ; Director of translational research

* 2018 – 2020 European Union (European Network of Excellence (IMI consortium; HARMONY)
Principal Investigator Jesus Maria Hernandez Rivas - Your Role in ProjectCo-leader of Lymphoma in
the Work package 5

EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Clinical research leadership	
<u>International</u>	
- Chair of the Scientific Committee of the French-Belgium cooperative Group GELA (Groupe d'Etude des Lymphomes des L'Adulte)	1996 – 2007
- Chair of the European Cooperative Group LYSA (the Lymphoma study association)	2012- 2020
- Co-Chair (with Pr. Randy Gascoyne) of the Lunenburg Lymphoma Biomarker Consortium (LLBC)	2003 - 2014
<u>National or Local</u>	
- Member of the steering committee of the Cancer Regional Cluster CLARA (Canceropôle Lyon Rhône-Alpes Auvergne)	2004 - 2011
- Project co-leader and member of the administrative board of the Foundation of scientific cooperation (competitive national call in 2007, budget 5000 k€) “Synergy Lyon Cancer”	2007 – 2020
- Project leader and Chair of the Administrative Board of the Institut Carnot CALYM (Consortium for the Acceleration of Innovation in Lymphoma), aimed to promote academy-industry collaborations	2011 – 2020
- Member of the Strategic Orientation Committee of Institut Carnot CALYM	2020 - present
Journal reviewer	Dates
New England Journal of Medecine, present	
Journal of Clinical Oncology, present	
Blood, present	
Lancet Oncology, present	
Haematologica, present	
European Journal of Haematology, present	
Annals of Oncology, present	
Annals of Hematology, present	
Clinical Cancer Research, present	
Cancer, present	
Leukemia & Lymphoma, present	
Nature Review in Clinical Oncology, present	
Blood Cancer Journal, present	
Member of the Editorial Board of Journal of Clinical Oncology	2010 – 2013
Member of the Editorial Board of Blood	2014 – 2018
Associate Editor “Haematologica”	2020 - present
Study section and grant reviews	
- Member of the Specialized Scientific Committee N°2 (oncology, cell biology) of INSERM (French NIH)	1995 - 1999
- Chair of the selection committee of the “Fondation contre le Leucémie” from the Fondation de France	2005 – 2008

<ul style="list-style-type: none"> - Grants review from the European Hematology Association - Habilitation Thesis Reviewer, Oslo University - Clinical research projects review, Swiss League against Cancer - Site visit review of the NCRI Lymphoma Clinical Study Group (UK) - External Advisor, Clinical Trials Planning Meeting (CTPM), NCI, Washington, US - Grant program reviews, French National Cancer Institute - Scientific Advisory Board of the Cancer Research Center of Nantes, France -- Chair of the Committee for the International Gilead Sciences Research Scholar Program in Hemato-Oncology - Member of the External Advisory Committee of the LEO (Lymphoma Epidemiology and Outcome) NCI grant (coordination J. Cerhan & C. Flowers) 	<p>2010- 2012 03/2013 2010; 2014 07/2014 11/2014 2014; 2016; 2017 01/2015 2014 – 2021 2015 - present</p>
<p>Invited presentations</p>	
<p><u>Educational sessions in international meetings</u></p>	
<ul style="list-style-type: none"> - American Society of Hematology annual meeting: “Clinical Features, Prognosis and Treatment of Follicular Lymphoma” - European Hematology Association annual meeting: “Treating diffuse large-B cell lymphoma: optimizing the use of anti-CD20 antibodies” - Pan Pacific Lymphoma Conference: “International Study of a Clinical-Biological Prognostic Index of DLBCL” - Pan Pacific Lymphoma Conference: “Is Follicular Lymphoma a Curable Lymphoma?” - European Hematology Association annual meeting: “The era of chemotherapy free treatment for Follicular lymphoma” - American Society of Clinical Oncology annual meeting: “Novel Agents in Treatment of Follicular Lymphoma” - ESMO- ECCO meeting “We Should Treat First Line Advanced Follicular Lymphoma without Chemotherapy” - Pan pacific Lymphoma Conference: “Should We Use Rituximab Maintenance in Indolent Lymphomas Other Than Follicular” - XXXVI World Congress of the International Society of Hematology “chemotherapy free treatment for Follicular lymphoma” - EHA annual meeting: “Relapsed aggressive lymphoma: Can we optimize the therapy” - International Conference on Malignant Lymphoma, Lugano 2019: “New drugs for NHL: beyond chemotherapy” - 25th EHA Congress “Jose Carreras Lecture” Follicular Lymphoma, from Genetics to the Clinic” - American Society of Hematology annual meeting: “Indolent lymphoma: Answers the Smoldering Questions” 	<p>12/2007 06/2008 06/2009 08/2011 06/2014 05/2015 09/2015 07/2016 04/2016 06/2017 06/2019 06/2020 12/2020</p>
<p><u>Invited lectures at the following National Society meetings:</u></p>	
<ul style="list-style-type: none"> - Belgium Society of Hematology, - Thai Society of Hematology - Brazilian Society of Hematology and Blood Transfusion - Dutch Society of Hematology (The Netherlands) - Portuguese Society for Hematology 	<p>2003 2006 11/2008 01/2010 02/2010</p>

- Brazilian Society of Hematology and Blood Transfusion	11/2010
- Thai Society of Hematology	02/2011
- British Society of Haematology	02/2011
- French Society of Hematology	03/2013
- Quebec Association of Oncologists & Hematologists	03/2013
- South African Society Cancer & Radiation Oncology/ South African Society Medical Oncology,	08/2013
- Thai Society of Hematology	03/2014
- Portuguese Society for Hematology	04/2014
- Czech Haematology And Transfusion Medicine Congress:	09/2018
- International Conference of the Korean Society of Hematology	03/2019
- Hematology Society of Taiwan, Taipei	08/2019
- Congress of the Polish Society of Haematology and Transfusion Medicine	09/2019
- Belgium Society of Hematology, “Pierre Stryckmans Lecture”	02/2020
- Colombian Association of Hematology & Oncology (Virtual)	09/2020
<u>Other relevant lectures at academic events (last 5 years)</u>	03/2014
- WHO Clinical Advisory Committee for Lymphocytic and Histiocytic Malignancies - Co-Chair of the committee; - Chicago	
- The 3rd TSH International Symposium “Lymphomas: East Meets West” Organized by the Thai Society of Hematology and the Thai Lymphoma Study Group ; Bangkok, Thailand :	05/2014
- 17th Meeting of the European Association for Haematopathology (EAHP); - Istanbul	10/2014
- European School of Hematology – New concepts in Lymphoid Malignancies, Greece	11/2014
- European School of Oncology – Educational Program June; Lugano	06/2015
- Lymphoma & Myeloma meeting New-York	10/2015
University Hospital of Lausanne: Distinguished lecture, Switzerland	11/2015
French- American Innovation Days, Boston, USA	02/2016
- 2 nd International Conference on New concepts in B-Cell Malignancies Estoril, European School of Hematology, Portugal	
- 3rd International Conference On New Concepts In Lymphoid Malignancies, European School of Hematology: Focus on CLL and Indolent Lymphoma; France	09/2016
- Memorial Sloan Kettering Symposium on Lymphoma State of the art in biology therapy, and patient care –New York	09/2017
- Closed Workshop: Follicular Lymphoma: Next 10 Years - North Berwick, Edinburgh,	06/2016
- 14-ICML Workshop (by invitation only) Organized in co-operation with American Association for Cancer Research and European School of Oncology; Lugano, Switzerland.	03/2017
- ESH Conference; Clinical Updates on CLL And Indolent Lymphoma, Paris	06/2017
- Seminars in Hematological Oncology Thirteenth International Educational Forum; Herzlia, Israel.	03/2018
- Pfreundschuh memorial symposium organized by the German Lymphoma Alliance, Göttingen, Germany	04/2018
	11/2018
	02/2019
	06/2019

- 1 st EBMT- EHA 1st European CAR T Cell Meeting - 15 th ICML Meeting, closed Workshop (liquid biopsies) - ESH International Conference: Immune and Cellular Therapies: Focus on Immune Based Therapeutic Concepts; Mandelieu, France - 4th Annual European Congress on Immunotherapies in Cancer – Barcelona, Spain - 2 nd EBMT- EHA European CAR T Cell Meeting, Sitges, Spain - The 18th International Workshop on Non-Hodgkin Lymphoma (iwNHL), - 2 nd Cellular Therapy Innovation Meeting CTI360 (Virtual) - ESH E-CONFERENCE: 2 nd How to Diagnose and Treat Lymphoma (Virtual) - 38 th Annual CFS®: Innovative Cancer Therapy for Tomorrow (Virtual)	09/2019 11/2019 01/2020 02/2020 02/2020 09/2020 10/2020 11/2020 11/2020
Other relevant institutional extramural activities	
<u>National</u> - Member of the « Pharmaco –economic group » of the French National Cancer Institute - Member of the Orientation Advisory Committee of the French National Cancer Institute - Member of the group “Lymphoid malignancies ” and Chair (2007-2009) of the French National Cancer Institute - Member of the Orientation Committee on the future of the « Clinical Research Program in Hospitals » (French Ministry of Health and Social Affairs) - co-Chair (with Pr. V Leblond) of the “White Paper” on “Oral Therapies in Onco-Hematology” - Member of the CAR-T experts group of the French National Cancer Institute	2006 - 2010 2007 – 2009 2005 – 2009 2012 - 2013 2015 - 2018 2017 – 2020
<u>International</u> - Member of the Scientific Committee for the Annual Meeting of the European Hematology Association - Chair of the Scientific Committee for the Annual Meeting of the European Hematology Association - Member of the ASCO Lymphoma / Myeloma Scientific Committee de l’ASCO (Chair in 2012) - Organisation and chair of the first Cell Therapy Innovation Congress in Lyon, France - Member of the “Clinical Advisory Committee for the WHO Classification of Lymphoid Neoplasms” - Member of “Clinical Advisory Committee for the WHO Classification of Lymphoid Neoplasms” - Member or the Medical Advisory Board of the Patient Representative Association « Lymphoma Coalition «	2006 – 2009 2008 2011- 2013 2019 2007 2014 2014 - present

PROFESSIONAL MEMBERSHIPS

Member/Officer/Fellow/Role	Organization	Dates
----------------------------	--------------	-------

Member	American Society of Hematology	1993
Member	American Society of Clinical Oncology	1993
Member	European Hematology Association	1994
Member	French Society of Hematology	1994

HONORS AND AWARDS

Name of award	Date awarded
Prix Roger Platel Mathieu from the Academy of Sciences, Literature and Arts of Lyon	2008
Chevalier de l'Ordre National du Merite (National Order of Merit)	2016
Belgium Society of Hematology - Pierre Stryckmans Lecture	2020
European Hematology Association - Jose Carreras Award	2020
Chicago Lymphoma Symposium - Clinical Keynote Speaker	2021
Memorial Sloan Kettering Cancer Center – Steven Greenberg Chair	2021

BIBLIOGRAPHY

I – Original research articles or reports in professional peer-reviewed journals

1. Trillet V, Revel D, Loire R, Pages J, Favrot M, Bonmartin A, **Salles G**, Marion P, Mornex JF, Cordier JF, Brune J: The detection of bone marrow involvement in small cell lung cancer using magnetic resonance imaging. J Clin Oncol 1988, 6:397-398.
<https://www.ncbi.nlm.nih.gov/pubmed/2828559>
2. **Salles G**, Herbrecht R, Tilly H, Berger F, Brousse N, Gisselbrecht C, Coiffier B: Aggressive primary gastrointestinal lymphomas : review of 91 patients treated with the LNH 84 regimen : a study of the Groupe d'Etude des Lymphomes Agressifs (G.E.L.A.). Amer J Med 1991, 90:77-84.
<https://www.ncbi.nlm.nih.gov/pubmed/1702581>
3. **Salles G**, Vial T, Archimbaud E: Anaphylactoid reaction with bronchospasm following intravenous cyclophosphamide administration. Ann Hematol 1991, 62:74-75.
<https://www.ncbi.nlm.nih.gov/pubmed/20319>
4. Chen CY, **Salles G**, Seldin MF, Kister A, Reinhertz EL, Shipp MA: Molecular characterization and chromosomal localization of the murine common acute lymphoblastic leukemia antigen (CALLA, CD10, Neutral endopeptidase 24.11). J Immunol 1992, 148:2817-2825.
<https://www.ncbi.nlm.nih.gov/pubmed/1374101>
5. **Salles G**, Chen CY, Reinherz EL, Shipp MA: CD10/NEP is expressed on Thy 1low B220+ murine B cell progenitors and functions to regulate stromal cell dependent lymphopoiesis. Blood 1992, 80:2021-2029. <https://www.ncbi.nlm.nih.gov/pubmed/1382716>
6. **Salles G**, Rodewald HR, Chin BS, Reinherz EL, Shipp MA: Inhibition of CD10/neutral endopeptidase 24.11 promotes B cell reconstitution and maturation in vivo. Proc Natl Acad Sci USA 1993, 90:7618-7622. <https://www.ncbi.nlm.nih.gov/pubmed/8356064>

7. **Salles G**, Zain M, Jiang WM, Boussioutis VA, Shipp MA: Alternatively spliced CD44 transcripts in diffuse large cell lymphomas : characterization and comparison with normal activated B cells and epithelial malignancies. *Blood* 1993, 82:3539-3547. <https://www.ncbi.nlm.nih.gov/pubmed/7505117>
8. Berger F, Felman P, Sonet A, **Salles G**, Bastion Y, Bryon PA, Coiffier B: Non follicular small B cell lymphomas : a heterogeneous group of patients with distinct clinical features and outcome. *Blood* 1994, 83:2829-2835. <https://www.ncbi.nlm.nih.gov/pubmed/8180379>
9. Dumontet C, Sonet A, Bastion Y, **Salles G**, Espinouse D, Coiffier B: Prevention of high dose L PAM induced mucositis by cryotherapy. *Bone Marrow Transplant* 1994 14:492-494. <https://www.ncbi.nlm.nih.gov/pubmed/7994283>
10. Bastion Y, Brice P, Haioun C, Sonet A, **Salles G**, Marolleau JP, Espinouse D, Reyes F, Gisselbrecht C, Coiffier B: Autologous peripheral blood stem cell transplantation (PBSCT) in 60 patients with advanced follicular lymphoma (FL). *Blood* 1995, 86:3257-3262. <https://www.ncbi.nlm.nih.gov/pubmed/7578992>
11. Hermine O, Haioun C, Lepage E, d'Agay M-F, Briere J, Lavignac C, Fillet G, **Salles G**, Marolleau JP, Diebold J, Reyes F, Gaulard P: Bcl2 protein expression in aggressive non-hodgkin's lymphoma. A new adverse prognostic factor ? A study on 290 cases. *Blood* 1996, 87:265-272. <https://www.ncbi.nlm.nih.gov/pubmed/8547651>
12. **Salles G**, Bienvenu J, Barbier Y, Bastion Y, Doche C, Warzocha K, Dumontet C, Rieux C, Coiffier B. Elevated levels of alpha-TNF and p55-R-TNF in lymphoma patients and their prognostic significance. *Br J Haematol* 1996, 93:352-359. <https://www.ncbi.nlm.nih.gov/pubmed/8639428>
13. Warzocha K, **Salles G**, Bienvenu J, Bastion Y, Dumontet C, Renard N, Neidhart-Berard E-M, Coiffier B. The Tumor Necrosis Factor ligand-Receptor system can predict outcome in lymphoma patients. *J Clin Oncol* 1997, 15:499-508. <https://www.ncbi.nlm.nih.gov/pubmed/9053471>
14. Bastion Y, Berger F, Felman P, **Salles G**, Dumontet C, Bryon PA, Coiffier B. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. *J Clin Oncol* 1997, 15: 1587-1594 . <https://www.ncbi.nlm.nih.gov/pubmed/9193357>
15. Thiéblemont C, Berger F, Bastion Y, Rieux C, **Salles G**, Felman P, Coiffier B. Mucosa-associated lymphoid tissue (MALT) gastrointestinal and non-gastrointestinal lymphoma patients have an identical outcome. *J Clin Oncol* 1997, 15 : 1624-1630. <https://www.ncbi.nlm.nih.gov/pubmed/9193362>
16. Ketterer N, **Salles G**, Espinouse D, Dumontet C, Neidhart-Berard E-M, Moullet I, Bouafia F, Berger F, Felman P, Coiffier B. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. *Ann Oncol*, 1997, 8:701-704. <https://www.ncbi.nlm.nih.gov/pubmed/9296227>
17. Warzocha K, Renard N, Charlot C, Bienvenu J, Coiffier B, **Salles G**. Identification of two lymphotoxin beta isoforms expressed in human lymphoid cell lines and non-Hodgkin's lymphomas. *Biochem Biophys Res Commun* 1997, 238:273-276. <https://www.ncbi.nlm.nih.gov/pubmed/9299492>
18. Callet-Bauchu E, Renard N, Gazzo S, Poncet C, Pagès J, **Salles G**, Coeur P, Felman P. The cytogenetic abnormality +i(3)(q10) is not restricted to binucleated cells in persistent polyclonal B-cell lymphocytosis. *Br J Haematol* 1997, 99:531-536. <https://www.ncbi.nlm.nih.gov/pubmed/9401061>
19. Warzocha K, Ribeiro P, Charlot C, Renard N, Coiffier B and **Salles G**. A new death receptor 3 (DR3) isoform: expression in human lymphoid cell lines and non-hodgkin's lymphomas. *Biochem Biophys Res Commun* 1998, 242:376-379. <https://www.ncbi.nlm.nih.gov/pubmed/9446802>

20. Ketterer N, **Salles G**, Raba M, Espinouse D, Sonet A, Tremisi P, Dumontet C, Moullet I, Neidhart-Berard E-M, Bouafia F, Coiffier B. High CD34+ cells counts decrease hematological toxicity of autologous peripheral blood progenitor cell transplantation. *Blood*, 1988, 91:3148-3155. <https://www.ncbi.nlm.nih.gov/pubmed/9558369>.
21. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Coiffier B, **Salles G**. Genetic polymorphisms in the tumor necrosis factor region and non-Hodgkin's lymphoma outcome. *Blood* 1998, 91:3574-3581. <https://www.ncbi.nlm.nih.gov/pubmed/9572991>
22. Dumontet C, Ketterer N, Espinouse D, Neidhart-Berard E-M, Moullet I, Thieblemont C, **Salles G**, Coiffier B. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma Bone Marrow Transplantation 1998, 21:1037-1041. <https://www.ncbi.nlm.nih.gov/pubmed/9632278>
23. Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard E-M, Coiffier B, **Salles G** (1998). Plasma levels of the tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. *Br J Cancer*, 1998, 77:2357-2362. <https://www.ncbi.nlm.nih.gov/pubmed/9649158>
24. Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F, Callet-Bauchu E, Berger F, Felman P, **Salles G**, Coiffier B. Mantle Cell Lymphoma ; a retrospective study of 121 cases. *Leukemia*, 1998, 12:1281-1287. <https://www.ncbi.nlm.nih.gov/pubmed/9697885>
25. Ketterer N, **Salles G**, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P, Thieblemont C, Durand B, Neidhardt-Bérard E-M, Samaha H, Rigal D and Coiffier B. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. *Br J of Haematol* 1998, 103:235-42. <https://www.ncbi.nlm.nih.gov/pubmed/9792315>
26. Ribeiro P, Renard N, Warzocha K, Charlot C, Jeandenat L, Callet-Bauchu E, Coiffier B, **Salles G**. CD40 regulation of death domain containing receptors and their ligands on lymphoma B-cells. *Br J of Haematol* 1998, 103:684-689. <https://www.ncbi.nlm.nih.gov/pubmed/9858217>
27. Moullet I, **Salles G**, Ketterer N, Dumontet C, Bouafia F, Neidhardt-Bérard E-M, Thieblemont C, Felman P, Coiffier B. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. *Ann Oncol* 1998, 9:1109-15. <https://www.ncbi.nlm.nih.gov/pubmed/9834824>
28. Ribeiro P, Bouafia F, Peaud P-Y, Blanc M, Salles B, **Salles G**, Coiffier B. Long-Term Outcome of Patients with Hairy Cell Leukemia treated with Pentostatin. *Cancer* 1999, 85:65-71. <https://www.ncbi.nlm.nih.gov/pubmed/9921975>
29. Ketterer N, Espinouse D, Chomar M, Dumontet C, Moullet I, Rieux C, Neidhardt-Bérard EM, Bouafia F, Coiffier B, **Salles G**. Patterns of infection following peripheral blood progenitor transplantation for lymphoid malignancies. *Am J Med*, 1999, 106: 191-197. <https://www.ncbi.nlm.nih.gov/pubmed/10230749>
30. Callet-Bauchu E, **Salles G**, Gazzo S, Poncet C, Morel D, Pagès D, Coiffier B, Coeur P, Felman P. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders : frequent occurrence of dicentric rearrangements and possible association with adverse outcome. *Leukemia* 1999,13:460-468. <https://www.ncbi.nlm.nih.gov/pubmed/10086737>
31. Renard N, Ribeiro P, Warzocha K, Rouviere R, Charlot C, Coiffier B, **Salles G**. Modulation of Co-stimulatory molecules on follicular lymphoma cells by TNF and CD40. *Leukemia Lymphoma* 1999, 33:331-41. <https://www.ncbi.nlm.nih.gov/pubmed/10221513>
32. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, **Salles G**, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B. International consensus conference on high dose therapy with hematopoietic stem cell transplantation in aggressive non

hodgkin's lymphomas: Report of the jury. J Clin Oncol 1999, 17:423-429
<https://www.ncbi.nlm.nih.gov/pubmed/10458261>

33. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, **Salles G**, Schmitz N, Symann M, Armitage JO, Coiffier B, Philip T. International Consensus Conference on high dose therapy with hematopoietic stem cell transplantation in aggressive non Hodgkin's lymphomas: report of the jury. Ann Oncol 1999 10:13-19
<https://www.ncbi.nlm.nih.gov/pubmed/10076716>
(note: this duplicate publications 36 & 37 were made in agreement with journal editors)
34. Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L, Rakestraw KM, Naeve C, Beckmann G, Weisenburger D, Sanger WG, Nowotny H, Vesely M, Callet-Bauchu E, **Salles G**, Dixit VM, Rosenthal A, Schlegelberger B, Morris SW. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain (CARD)-containing gene, in MALT lymphoma with t(1;14)(p22;q32) 1999, Nature Genetics, 22 : 63-68. <https://www.ncbi.nlm.nih.gov/pubmed/10319863>
35. Ketterer N, Sonnet A, Dumontet C, Moullet I, Thieblemont C, Espinouse D, Bouafia F, Coiffier B, **Salles G**. Toxicities after peripheral blood progenitor transplantation for lymphoid malignancies. 1999, Bone Marrow Transplantation, 23:1309-1315.
<https://www.ncbi.nlm.nih.gov/pubmed/10414921>
36. Dumontet C, Draï J, Bienvenu J, Berard EN, Thieblemont C, Bouafia F, Bayle F, Moullet I, **Salles G**, Coiffier B. Profiles and prognostic values of LDH isoenzymes in patients with non Hodgkin's lymphoma. Leukemia 1999 13:811-817. <https://www.ncbi.nlm.nih.gov/pubmed/10374888>
37. Callet-Bauchu E, Gazzo C, Poncet C, Pagès J, Morel D, Alliot C, Coiffier B, Coeur P, **Salles G**, Felman P. Distinct Chromosome 3 Abnormalities in Persistent Polyclonal B-Cell Lymphocytosis. Gene Chromosomes & Cancer, 1999 26:221-8. <https://www.ncbi.nlm.nih.gov/pubmed/10502320>
38. Renard N, Valladeau J, Barthelemy C, Ribeiro P, Berger F, Saeland S, **Salles G**. Characterization of germinal center dendritic cells in follicular lymphoma. Exp Hematol, 1999, 27:1768-1775 .
<https://www.ncbi.nlm.nih.gov/pubmed/10641594>
39. Johnson PW, Swinbank K, MacLennan S, Colomer D, Debuire B, Diss T, Gabert J, Gupta RK, Haynes A, Kneba M, Lee MS, Macintyre E, Mensink E, Moos M, Morgan GJ, Neri A, Johnson A, Reato G, **Salles G**, van't Veer MB, Zehnder JL, Zucca E, Selby PJ, Cotter FE. Variability of polymerase chain reaction detection of the bcl 2 IgH translocation in an international multicentre study. Ann Oncol 1999 10:1349-54. <https://www.ncbi.nlm.nih.gov/pubmed/10631464>
40. Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C, Monneret G, Gutowski M-C, Coiffier B, **Salles G**. Factors predicting chemotherapy induced myelosuppression : role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 2000, 18: 325-331.
<https://www.ncbi.nlm.nih.gov/pubmed/10637246>
41. Thiéblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, **Salles G**, Coiffier B. Mucosa associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000 95: 802-806 . <https://www.ncbi.nlm.nih.gov/pubmed/10648389>
42. Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon P-A, **Salles G**, Callet Bauchu E, and Coiffier B. Non MALT marginal zone B cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000 95: 1950-1956.
<https://www.ncbi.nlm.nih.gov/pubmed/10706860>
43. Mounier N, Haioun C, Cole BF, Gisselbrecht C, Sebban C, Morel P, Marit G, Bouabdallah R, Ravoet C, **Salles G**, Reyes F, Lepage F for the GELA. Quality of life adjusted survival (Q-Twist) analysis of high dose therapy with autologous bone marrow transplantation versus sequential

- chemotherapy for aggressive lymphoma patients in first complete remission : the GELA LNH87-2 study. *Blood* 2000 95 :2387-3692. <https://www.ncbi.nlm.nih.gov/pubmed/10845898>
44. Michallet M, Philip T, Philip I, Godinot H, Sebban C, **Salles G**, Thiebaut A, Biron P, Lopez F, Mazars P, Roubi N, Leemhuis T, Hanania E, Reading C, Fine G, Atkinson K, Juttner C, Coiffier B, Fiere D, Archimbaud E. Transplantation With Selected Autologous Peripheral Blood CD34+Thy-1+ Hematopoietic Stem Cells (HSCs) in Multiple Myeloma: Impact Of the HSC Dose On Engraftment, Safety and Immune Reconstitution. *Exp Hematol* 2000, 28:858-70.
<https://www.ncbi.nlm.nih.gov/pubmed/10907648>
 45. Warzocha K, Ribeiro P, Renard N, Bienvenu J, Charlot C, Coiffier B, **Salles G**. Expression of the tumor necrosis factor, lymphotoxin ligand-receptor systems genes in non-Hodgkin's lymphomas. *Cancer Immunol Immunother* 2000, 49:469-75. <https://www.ncbi.nlm.nih.gov/pubmed/11092613>
 46. Haioun C, Lepage E, Gisselbrecht C, **Salles G**, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Brière J, Gaulard P, Reyes F. Survival benefit of high dose therapy in poor risk aggressive non-hodgkin's lymphoma : final analysis of the prospective LNH87-2 protocol. *J Clin Oncol* 2000, 18:3025-3030. <https://www.ncbi.nlm.nih.gov/pubmed/10944137>
 47. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, **Salles G**, Altieri DC, and Molina T. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. *Blood* 2000, 96 :921-1925.
<https://www.ncbi.nlm.nih.gov/pubmed/10961895>
 48. Dumontet C, Thieblemont C, Espinouse D, Bouafia F, Hequet O, **Salles G**, and Coiffier B. A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors. *Leukemia* 2000, 14 :2159-2165. <https://www.ncbi.nlm.nih.gov/pubmed/11187906>
 49. Colombat P, **Salles G**, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Mathieu-Boue A, Benzohra A, Solal-Celigny P. Rituximab (anti-CD20 monoclonal antibody) as single first line therapy of follicular lymphoma patients with a low tumor burden : clinical and molecular evaluation. *Blood*, 2001, 97 :101-106.
<https://www.ncbi.nlm.nih.gov/pubmed/11133748>
 50. Dumontet C, Draï J, Thieblemont C, Hequet O, Espinouse D, Bouafia F, **Salles G**, Coiffier B. The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide. *Br J Haematol*, 2001, 112:405-409 (A).
<https://www.ncbi.nlm.nih.gov/pubmed/11167839>
 51. Baseggio L, Bienvenu J, Charlot C, Picollet J, Felman P, Coiffier B, **Salles G**. Higher LPS-stimulated TNF-alpha mRNA levels in Peripheral Blood Mononuclear Cells from non-Hodgkin's Lymphoma Patients. *Experimental Hematology*, 2000, 29:330-338
<https://www.ncbi.nlm.nih.gov/pubmed/11274761>
 52. Nicolas L, Monneret G, Debard A-L, Blesius A, Gutowski M-C, **Salles G**, Bienvenu J. Human gammadelta T cells express a higher TCR/CD3 complex density than alphabeta T cells. *Clinical Immunology*, 2001, 98:358-363 <https://www.ncbi.nlm.nih.gov/pubmed/11237559>
 53. Langouët A-M, Brice P, Simon D, Bocaccio C, Munck J-N, Fillet G, Peny A-M, **Salles G**, Quesnel B, Lefrere F, Reyes F, Gisselbrecht C. Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma : a prospective study of 123 patients. *Hematol J*, 2001, 2 :81-86.
<https://www.ncbi.nlm.nih.gov/pubmed/11423999>

54. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, **Salles G**, Coiffier B. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. *Br J Haematol* 2001, 113:772-8
<https://www.ncbi.nlm.nih.gov/pubmed/11380469>
55. Baseggio L, Charlot C, Picollet J, Bienvenu J, **Salles G**. High circulating tumor necrosis factor levels correlate with increased levels of soluble CD14 in patients with non-Hodgkin's lymphoma. *Haematologica*. 2001 Jul;86(7):774-75. <https://www.ncbi.nlm.nih.gov/pubmed/11454540>
56. Bienvenu J, Chvetzoff R, **Salles G**, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solla-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B for the GELA. Tumor necrosis factor alpha is the major biological event associated with rituximab treatment. *Hematol J*, 2001, 2:378-384. <https://www.ncbi.nlm.nih.gov/pubmed/11920277>
57. Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, **Salles G**. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the the Groupe d'Etudes des Lymphomes de L'Adulte H89 trial. *J Clin Oncol*, 2002, 20: 467-475.
<https://www.ncbi.nlm.nih.gov/pubmed/11786576>
58. Cartron G, Dacheux L, **Salles G**, Solal-Celigny P, Bardos P, Colombat P and Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc γ R1IIa gene. *Blood*, 2002, 99:754-758. <https://www.ncbi.nlm.nih.gov/pubmed/11806974>
59. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, **Salles G**, Gaulard P, Reyes F, Gisselbrecht C. CHOP Plus Rituximab Compared with CHOP Chemotherapy in Elderly Patients With Diffuse Large B-Cell Lymphoma. A Groupe d'Etude des Lymphomes de l'Adulte Study. *The New England Journal of Medicine*, 2002, 346:235-42.
<https://www.ncbi.nlm.nih.gov/pubmed/11807147>
60. Thieblemont C, Mayer A, Dumontet C, Barbier Y, Callet-Bauchu E, Felman P, Berger F, Ducottet X, Martin C, **Salles G**, Orgiazzi J, Coiffier B. Primary thyroid lymphoma is a heterogeneous disease. *J Clin Endocrinol Metab*. 2002, 87:105-11. <https://www.ncbi.nlm.nih.gov/pubmed/11788631>
61. Baseggio L, Charlot C, Bienvenu J, Felman P, **Salles G**. TNF-alpha mRNA stability in human peripheral blood cells after LPS stimulation. *European Cytokine Network*, 2002, 13:92-8.
<https://www.ncbi.nlm.nih.gov/pubmed/11956026>
62. Leroy K, Haioun C, Lepage E, Le Métayer N, Berger F, Labouyrie E, Meignin V, Petit B, Bastard C, **Salles G**, Gisselbrecht C, Reyes F, Gaulard P, for the Groupe d'Etude des Lymphomes de l'Adulte (GELA). p53 Gene Mutations Are Associated With Poor Survival In Low And Low-Intermediate Risk Diffuse Large B-Cell Lymphomas. *Ann Oncol* 2002, 13:1108-15
<https://www.ncbi.nlm.nih.gov/pubmed/12176791>
63. Juszczynski P, Kalinka E, Bienvenu J, Woszczek G, Borowiec M, Robak T, Kowalski M, Lech-Maranda E, Baseggio L, Coiffier B, **Salles G**, Warzocha K. Human Leukocyte Antigens Class II (HLA DRB1) And Tumor Necrosis Factor Genetic Polymorphisms Are Independent Predictors Of Non-Hodgkin's Lymphoma Outcome. *Blood*, 2002, 100:3037-3400.
<https://www.ncbi.nlm.nih.gov/pubmed/12351419>
64. Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, Arcache J, Callet-Bauchu E, **Salles G**, Coiffier B. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. *Clin Lymphoma* 2002, 3:41-7 <https://www.ncbi.nlm.nih.gov/pubmed/12141954>
65. Thieblemont C, Chettab K, Felman P, Callet-Bauchu E, Traverse-Glehen A, Berger F, Dumontet C, Cerutti C, Baseggio L, **Salles G**, Paultre C, Coiffier B, McGregor JL. Identification and validation of

- 7 genes for the differential diagnosis of small B-cell lymphomas (small lymphocytic lymphoma, marginal zone B-cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis. *Leukemia*, 2002, 16:2326-9. <https://www.ncbi.nlm.nih.gov/pubmed/12399979>
66. Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P, Hequet O, Espinouse D, **Salles G**, Roy P, Eljaafari-Corbin A, Du Manoir-Baumgarten C, Coiffier B. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. *Bone Marrow Transplant*, 2002 30:769-75. <https://www.ncbi.nlm.nih.gov/pubmed/12439700>
67. Juszczynski P, Woszczek G, Borowiec M, Kowalski M, Robak T, **Salles G**, Warzocha K. Comparison Study for Genotyping of a Single Nucleotide Polymorphism in the Tumor Necrosis Factor Promoter Gene. *Diag Mol Path* 2002; 11:228-233 <https://www.ncbi.nlm.nih.gov/pubmed/12459639>
68. Gazzo S, Baseggio L, Coignet L, Poncet C, Morel D, Coiffier B, Felman P, Berger F, **Salles G**, Callet-Bauchu E. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. *Haematologica* 2003;88:31-8. <https://www.ncbi.nlm.nih.gov/pubmed/12551824>
69. Thieblemont C, Dumontet C, Bouafia F, Hequet O, Arnaud P, Espinouse D, Felman P, Berger F, **Salles G**, Coiffier B. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. *Leuk Lymphoma* 2003, 44:257-62. <https://www.ncbi.nlm.nih.gov/pubmed/12688342>
70. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, de Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RCT, Li S, **Salles G**, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin's lymphoma. *Blood* 2003, 102:3871-9. <https://www.ncbi.nlm.nih.gov/pubmed/12933571>
71. Guyomard S, **Salles G**, Coudurier M, Rousset H, Coiffier B, Bienvenu J, Fabien N. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. *Br J Haematol*. 2003, 123:90-9. <https://www.ncbi.nlm.nih.gov/pubmed/14510947>
72. Baseggio L, Bartholin L, Chantome A, Charlot C, Rimokh R, **Salles G**. Allele-specific binding to the 308 single nucleotide polymorphism site in the tumor necrosis factor-alpha promoter. *Eur J Immunogenet* 2004, 31: 15-19 . <https://www.ncbi.nlm.nih.gov/pubmed/15009176>
73. Thieblemont C, Nasser V, Felman P, Leroy K, Gazzo S, Callet-Bauchu E, Loricod B, Granjeau S, Gaulard P, Haioun C, Traverse-Glehen A, Baseggio L, Bertucci F, Birnbaum D, Minvielle S, Avet-Loiseau H, **Salles G**, Coiffier B, Berger F, Houlgatte R. Small Lymphocytic Lymphoma (SLL), Marginal Zone B-Cell Lymphoma (MZL), Mantle Cell Lymphoma (MCL) Exhibit Distinct Gene-Expression Profiles Allowing Molecular Diagnosis. *Blood* 2004, 103:2727-37. <https://www.ncbi.nlm.nih.gov/pubmed/14630827>
74. Hequet O, Le QH, Moullet I, Pauli E, **Salles G**, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F, Coiffier B. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. *J Clin Oncol* 2004, 22:1864-71. <https://www.ncbi.nlm.nih.gov/pubmed/15143078>
75. Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouaffia F, Alhusein Q, Antal D, Salles G and B Coiffier. Rituximab-related late-onset neutropenia after autologous stem cell

- transplantation for aggressive non-Hodgkin 's lymphoma. Bone Marrow Transplantation 2004, 33:921-3. <https://www.ncbi.nlm.nih.gov/pubmed/15034544>
76. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, **Salles G**. The IL-10 gene promoter polymorphisms influence the outcome of diffuse large B-cell lymphoma. Blood 2004, 103:3529-3534 . <https://www.ncbi.nlm.nih.gov/pubmed/14701701>
 77. Thieblemont C, Bouafia F, Hornez E, Dumontet C, Tartas S, Antal D, Lemieux B, Traulle C, Espinouse D, **Salles G**, Coiffier B. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004, 45:711-4. <https://www.ncbi.nlm.nih.gov/pubmed/15160944>
 78. Lemieux B, Bouafia F, Thieblemont C, Hequet O, Arnaud P, Tartas S, Traulle C, **Salles G**, Coiffier B. Second Treatment with Rituximab in B-Cell Non-Hodgkin's Lymphoma: Efficacy and Toxicity on 41 Patients Treated at CHU-Lyon Sud. Hematol J 2004, 5:467-71 . <https://www.ncbi.nlm.nih.gov/pubmed/15570286>
 79. Bouafia F, Draï J, Bienvenu J, Thieblemont C, Espinouse D, **Salles G**, Coiffier B. Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies. Bull Cancer 2004, 91: 229-240. <https://www.ncbi.nlm.nih.gov/pubmed/15381461>
 80. Seve P, Renaudier P, Sascó AJ, Dumontet C, **Salles G**, Coiffier B, Zoulim F, Broussolle C, Trepo C. Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France. Eur J Gastroenterol Hepatol. 2004, 16:1361-5. <https://www.ncbi.nlm.nih.gov/pubmed/15550490>
 81. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, **Salles G**, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105:1851-61. <https://www.ncbi.nlm.nih.gov/pubmed/15550490>
 82. Traverse-Glehen A, Davi F, Ben Simon E, Callet-Bauchu E, Felman P, Baseggio L, Gazzo S, Thieblemont C, Charlot C, Coiffier B, Berger F, **Salles G**. Analysis of VH genes in 49 marginal zone lymphoma cases reveals a marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica 2005, 90:473-481. <https://www.ncbi.nlm.nih.gov/pubmed/15820942>
 83. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, **Salles G**, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma. J Clin Oncol 2005, 18:4117-26 . <https://www.ncbi.nlm.nih.gov/pubmed/15867204>
 84. Gazzo S, Poncet C, Felman P, Berger F, Charlot C, **Salles G**, Magaud JP, Callet-Bauchu E. Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma. Haematologica 2005, 90:1708-9. <https://www.ncbi.nlm.nih.gov/pubmed/16330452>
 85. E Callet-Bauchu, L Baseggio, P Felman, A Traverse-Glehen, F Berger, D Morel, S Gazzo, C Poncet, C Thieblemont, B Coiffier, JP Magaud, and G Salles. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia, 2005 19:1818-23. <https://www.ncbi.nlm.nih.gov/pubmed/16094418>
 86. Bencimon C, **Salles G**, Moreira A, Guyomard S, Coiffier B, Bienvenu J, Fabien N. Prevalence of anticentromere F protein autoantibodies in 347 patients with non Hodgkin's lymphoma. Ann N Y Acad Sci. 2005;1050:319-26. <https://www.ncbi.nlm.nih.gov/pubmed/16014548>

87. Ghielmini, K, Rufibach, G, Salles, L, Leoncini-Francini, C, Leger-Falandry, S, Cogliatti, M, Fey, G, Martinelli, R, Stahel, A, Lohri, N, Ketterer, M, Wernli, T, Cerny & S.-F. Hsu Schmitz Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). *Ann Oncol* 2005, 16:1675-82. <https://www.ncbi.nlm.nih.gov/pubmed/16030029>
88. Thieblemont C, Antal D, Lacotte-Thierry L, Delwail V, Espinouse D, Michallet A-S, Tartas S, Bouafia F, Giraud C, **Salles G**, Guilhot F, Coiffier B. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. *Cancer* 2005, 104:1434-41. <https://www.ncbi.nlm.nih.gov/pubmed/16104036>
89. Stankovic K, Sarrot-Reynauld F, Puget M, Massot C, Ninet J, Lorcerie B, Dupond JL, **Salles G**, Durieu I, Vital Durand D, Rousset H. Systemic mastocytosis: Predictable factors of poor prognosis present at the onset of the disease. *Eur J Intern Med.* 2005;16:387-90. <https://www.ncbi.nlm.nih.gov/pubmed/16198895>
90. Traverse-Glehen, A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Thieblemont C, Coiffier B, **Salles G**, Berger F. Nodal marginal zone B-cell lymphoma : a large B-cell-rich clinicopathological entity, a report of 21 cases. *Histopathology* 2006, 48:162-73. <https://www.ncbi.nlm.nih.gov/pubmed/16405665>
91. Baseggio L, Berger F, Morel D, Goedert G, **Salles G**, Magaud J-P, Felman P. Identification of circulating CD10 positive T-cells contributes to the diagnosis of angioimmunoblastic T-cell lymphoma. *Leukemia* 2006, 20:296-303. <https://www.ncbi.nlm.nih.gov/pubmed/16341050>
92. Lech-Maranda E, Bienvenu J, Michallet AS, Houot R, Robak T, Coiffier B, **Salles G**. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. *Eur Cytokine Netw.* 2006, 17:60-66. <https://www.ncbi.nlm.nih.gov/pubmed/16613764>
93. Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa A-M, Vandenberghe M, Fischer A, Morschhauser F, **Salles G**, Feremans W, Vilmer E, Peraldi E, Lang P, Lebranchu Y, Oksenhendler E, Garnier J-L, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied. Efficacy And Safety Of Rituximab In B-Cell Post-Transplant Lymphoproliferative Disorders: Results Of A Prospective Multicentre Phase II Study. *Blood* 2006, 107:3053-7. <https://www.ncbi.nlm.nih.gov/pubmed/16254143>
94. Benoît Ballester, Olivier Ramuz, Christian Gisselbrecht, Gaëlle Doucet, Laurence Loï, Béatrice Loriod, François Bertucci, Daniel Birnbaum, Reda Bouabdallah, Elisabeth Devilard, Pierre Brousset, Françoise Berger, Gilles Salles, Karen Leroy, Josette Brière, Rémi Houlgatte, Philippe Gaulard, Luc Xerri. Gene Expression Profiling Identifies Molecular Subgroups Among Nodal Peripheral T-Cell Lymphomas. *Oncogene* 2006, 25:1560-70 <https://www.ncbi.nlm.nih.gov/pubmed/16288225>
95. S Niclot, Q Pruvot, C Besson, D Savoy, E MacIntyre, G Salles, N Brousse, B Varet, P Landais, P Taupin, C Junien and D Baudry-Bluteau. Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. *Blood*, 2006, 108:278-85 . <https://www.ncbi.nlm.nih.gov/pubmed/16410450>
96. Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J, Rousset H, **Salles G**, Broussolle C, Seve P. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. *Lupus.* 2006;15:223-31. <https://www.ncbi.nlm.nih.gov/pubmed/16686262>

97. Fouchardiere AD, Gazzo S, Balme B, Chouvet B, Felman P, Coiffier B, **Salles G**, Callet-Bauchu E, Berger F. Cytogenetic and Molecular Analysis of 12 Cases of Primary Cutaneous Marginal Zone Lymphomas. *Am J Dermatopathol*. 2006 28:287-292.
<https://www.ncbi.nlm.nih.gov/pubmed/16871031>
98. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, Tilly H, Feugier P, Bouabdallah R, Doyen C, **Salles G**, Coiffier B. Standard chemotherapy with interferon compared to CHOP followed by high-dose therapy with autologous stem cell transplant in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the GELA. *Blood* 2006, 108:2540-4 . <https://www.ncbi.nlm.nih.gov/pubmed/16835383>
99. Ghesquières H, Berger F, Felman P, Callet-Bauchu E, Bryon P-A, Thieblemont C, Traverse-Glehen A, Baseggio L, Coiffier B, **Salles G**. Clinicopathological characteristics and outcome of Diffuse Large B-Cell Lymphomas presenting with features of Transformed Low Grade Lymphomas At Diagnosis. *J Clin Oncol* 2006, 24:5234-41. <https://www.ncbi.nlm.nih.gov/pubmed/17043351>
100. Baseggio L, Berger F, Monneret G, Magaud J-P, **Salles G**, Felman P. Low Expression Of Tcr- $\gamma\delta$ /Cd3 Complex Characterize Neoplastic $\gamma\delta$ T-Cell. *Haematologica*, 2006, 91:1717-9.
<https://www.ncbi.nlm.nih.gov/pubmed/17145615>
101. van Krieken JH, Langerak AW, Macintyre EA, Kneba M, Hodges E, Sanz RG, Morgan GJ, Parreira A, Molina TJ, Cabecadas J, Gaulard P, Jasani B, Garcia JF, Ott M, Hannsmann ML, Berger F, Hummel M, Davi F, Bruggemann M, Lavender FL, Schuurin E, Evans PA, White H, **Salles G**, Groenen PJ, Gameiro P, Pott C, Dongen JJ. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: - Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. *Leukemia*. 2007 21:201-6 . <https://www.ncbi.nlm.nih.gov/pubmed/17170732>
102. Evans PA, Pott C, Groenen PJ, **Salles G**, Davi F, Berger F, Garcia JF, van Krieken JH, Pals S, Kluin P, Schuurin E, Spaargaren M, Boone E, Gonzalez D, Martinez B, Villuendas R, Gameiro P, Diss TC, Mills K, Morgan GJ, Carter GI, Milner BJ, Pearson D, Hummel M, Jung W, Ott M, Canioni D, Beldjord K, Bastard C, Delfau-Larue MH, van Dongen JJ, Molina TJ, Cabecadas J. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. *Leukemia*. 2007 21:207-14. <https://www.ncbi.nlm.nih.gov/pubmed/17170731>
103. de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Norton A, Hagenbeek A, Horning S, Lister A, Raemaekers J, Gascoyne R, Salles G, Weller E. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications. A study from the Lunenburg Lymphoma Biomarker Consortium. *J Clin Oncol*, 2007, 25:805-12.
<https://www.ncbi.nlm.nih.gov/pubmed/17327602>
104. Nowak J, Kalinka E, Juszczynski P, Bilinski P, Mika-Witkowska R, Zajko M, Bienvenu J, Coiffier B, **Salles G** and Warzocha K. Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. *Genes, Chromosomes and Cancer*, 2007, 46:500-7 . <https://www.ncbi.nlm.nih.gov/pubmed/17311253>
105. Casasnovas R-O, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay J-Y, Voillat L, Lederlin P, Stamatoullas A, Bienvenu J, Guiguet M, Intrator L, Grandjean M, Brière J, Ferme C, and **Salles G**. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin lymphoma. *J Clin Oncol*, 2007, 25:1732-40.
<https://www.ncbi.nlm.nih.gov/pubmed/17389336>
106. Murga Penas EM, Callet-Bauchu E, Ye H, Hinz K, Albert N, Copie-Bergman C, Gazzo S, Berger F, **Salles G**, Bokemeyer C, Du MQ, Dierlamm J. The translocations t(6;18;11)(q24;q21;q21)

- and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas. *Haematologica*. 2007, 92:405-9 . <https://www.ncbi.nlm.nih.gov/pubmed/17339192>
107. Plonquet A, Haioun C, Jais J-P, Debard A-L, **Salles G**, Bene M-C, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet J-P, Emile J-F, Gisselbrecht C, Delfau-Larue M-H for the GELA. Peripheral Blood Natural Killer Cell Count Is Associated With Clinical Outcome In Patients With aaIPI 2-3 Diffuse Large B-Cell Lymphoma. *Ann Oncol* 2007 18:1209-15 . <https://www.ncbi.nlm.nih.gov/pubmed/17496307>
 108. Callet-Bauchu E, **Salles G**, Gazzo S, Dalle S, Berger F, Hayette S. Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sezary syndrome. *Haematologica*. 2007 92:1277-8. <https://www.ncbi.nlm.nih.gov/pubmed/17768128>
 109. Traverse-Glehen A, Verney A, Baseggio L, Felman P, Callet-Bauchu E, Thieblemont C, Ffrench M, Magaud JP, Coiffier B, Berger F, **Salles G**. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. *Leukemia*. 2007; 21:1821-4. <https://www.ncbi.nlm.nih.gov/pubmed/17476282>
 110. Gazzo S, Chudoba I, Traverse-Glehen A, Baseggio L, Felman P, Berger F, **Salles G**, Hayette S, Magaud JP, Callet-Bauchu E. Detailed characterization of 7q deletions by multicolor banding (mBAND) in marginal zone cell lymphoma. *Cancer Genet Cytogenet*. 2007, 175:159-65. <https://www.ncbi.nlm.nih.gov/pubmed/17556073>
 111. Lachenal F, Berger F, Ghesquières H, Biron P, Hot A, Callet-Bauchu E, Chassagne C, Coiffier B, Durieu I, Rousset H, **Salles G**. Angioimmunoblastic T-cell lymphoma : clinical and biological features at diagnosis in 77 patients, *Medicine* 2007 86:282-92 . <https://www.ncbi.nlm.nih.gov/pubmed/17873758>
 112. Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, **Salles G**, Feremans W, Apperley J, Samson D, Björkstrand B, Niederwieser D, Gahrton G, Pico J-L, Goldschmidt H for the European Group for Blood and Marrow Transplantation (EBMT). CD34+ selection does not improve outcome of autologous transplantation in myeloma and relapse risk is not correlated with infused tumour cell load: long term follow-up of an EBMT phase III study. *Haematologica* 2007, 92:1083-90 <https://www.ncbi.nlm.nih.gov/pubmed/17640853>
 113. Fermé C, Eghbali H, Meerwaldt J-H, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van Den Neste, E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, **Salles G**, Noordijk EM, Creemers G-J, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans J-C, Viseu F, Baars J W, Poortmans P, Lugtenburg P-J, Carrie C, Jaubert J, Henry-Amar M. EORTC–GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. *N Engl J Med.*, 2007, 357:1916-27. <https://www.ncbi.nlm.nih.gov/pubmed/17989384>
 114. Rolland D, Camara-Clayette V, Barbarat A, **Salles G**, Coiffier B, Ribrag V, Thieblemont C. Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. *Cancer Chemother Pharmacol*. 2008 Apr;61(5):855-63 . <https://www.ncbi.nlm.nih.gov/pubmed/17639395>
 115. Raynaud P, Caulet-Maugendre S, Foussard C, **Salles G**, Moreau A, Rossi JF, Patey M, Rousselet MC, Bene MC, Damotte D, Cornillet Lefebvre P, Martin A, Costes V; the GOELAMS group (Groupe Ouest Est des Leucemies et Autres Maladies du Sang). T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy? *Hum Pathol*. 2008, 39:194-200 . <https://www.ncbi.nlm.nih.gov/pubmed/17949786>

116. Canioni D, **Salles G**, Mounier N, Brousse N, Keuppens M, Morschhauser F, Lamy T, Sonet A, Rousselet M-C, Foussard C, Xerri L. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled in the FL2000 GELA-GOELAMS trial. *J Clin Oncol*, 2008, 26:440-6 .
<https://www.ncbi.nlm.nih.gov/pubmed/18086798>
117. Nowak J, Kalinka-Warzocha E, Juszczynski P, Mika-Witkowska R, Zajko M, Graczyk-Pol E, Coiffier B, **Salles G**, Warzocha K. Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome. *Tissue Antigens*, 2008, ;71:16-26. <https://www.ncbi.nlm.nih.gov/pubmed/17971052>
118. Traverse-Glehen A, Baseggio L, Callet-Bauchu E, Morel D, Gazzo S, Ffrench M, Verney A, Rolland D, Thieblemont C, Magaud J-P, **Salles G**, Coiffier B, Berger F, Felman P. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinico-pathological and molecular entity *Blood*, 2008, 111:2253-60. <https://www.ncbi.nlm.nih.gov/pubmed/18042795>
119. Poncet D, Belleville A, T'kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral H, Callet-Bauchu E, **Salles G**, Sabatier L, Delic J, Gilson E. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B chronic lymphocytic leukemia. *Blood*. 2008, 111:2388-91. <https://www.ncbi.nlm.nih.gov/pubmed/18077792>
120. Thieblemont C, Grosseuvre A, Houot R, Broussais-Guillaumont F, **Salles G**, Traullé C, Espinouse D, Coiffier B. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. *Ann Oncol*. 2008 Apr;19(4):774-9
<https://www.ncbi.nlm.nih.gov/pubmed/18065404>
121. Morel P, Gaulard P, Gisselbrecht C, Ferme C, **Salles G**, Tilly H, Brière J, Copin MC, Lederlin P, Hermine O, Theate I, Haioun C, Mounier N. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. *Ann Oncol*. 2008, 19:560-5. <https://www.ncbi.nlm.nih.gov/pubmed/18096567>
122. Cartron G, Ohresser M, **Salles G**, Solal-Céligny P, Colombat P, Watier H. Neutrophil role in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment. *Ann Oncol*. 2008 ; 19:1485-7 .
<https://www.ncbi.nlm.nih.gov/pubmed/18408222>
123. Bathelier E, Thomas L, Balme B, Coiffier B, **Salles G**, Berger F, Ffrench M, Sebban C, Biron P, Dalle S. Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B-cell lymphoma. *Br J Dermatol*. 2008 Aug;159(2):498-500 .
<https://www.ncbi.nlm.nih.gov/pubmed/18547317>
124. Morschhauser F, Radford J, van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens P, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani P-L, van Oers M H.J., van Putten W, Bischof-Delaloye A, Rohatiner A, **Salles G**, Kuhlmann J, Hagenbeek A. Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. *J Clin Oncol* 2008, 26:5156-64
<https://www.ncbi.nlm.nih.gov/pubmed/18854568>
125. Morschhauser F, Brice P, Ferme C, Divine M, **Salles G**, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, Andre M, Jais J-P, Cazals-Hatem D, Gisselbrecht C. Risk-Adapted Salvage Treatment with Single or Tandem Autologous Stem-Cell Transplantation for First-Relapse/Refractory Hodgkin Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA-SFGM Study Group. *J Clin Oncol*, 2008, 26:5980-7.
<https://www.ncbi.nlm.nih.gov/pubmed/19018090>

126. Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Brière J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, Bastard C, Coiffier B, **Salles G**, Leroy K. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. *Leukemia*. 2008, 22:1917-24 <https://www.ncbi.nlm.nih.gov/pubmed/18615101>
127. **Salles G**, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, Haioun C, Brice P, Mahe B, Bouabdallah R, Audhuy B, Ferme C, Dartigeas C, Feugier P, Sebban C, Xerri L, Foussard C. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. *Blood*. 2008, 112:4824-31 <https://www.ncbi.nlm.nih.gov/pubmed/18799723>
128. Johnston A, **Salles G**, Espinouse D, Felman P, André P, Berger F, Coiffier B. Epstein-Barr Virus-Induced Lymphoproliferative Disorder After Rituximab Combined with CHOP Therapy. *Clin Lymphoma Myeloma*. 2008 Dec;8(6):356-8. <https://www.ncbi.nlm.nih.gov/pubmed/19064401>
129. Chebel A, Bauwens S, Gerland L-M, Belleville A, Urbanowicz1 I, Roborel de Climens A, Tourneur Y, Chien W-W, Catallo R, **Salles G**, Gilson E, Ffrench M. Telomere uncapping during in vitro T-lymphocyte senescence. *Aging Cell* 2009; 8:52-64 . <https://www.ncbi.nlm.nih.gov/pubmed/19077045>
130. Kaddar T, Rouault JP, Chien WW, Chebel A, Gadoux M, **Salles G**, Ffrench M, Magaud JP. Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation. *Biol Cell*. 2009; 101:511-24 <https://www.ncbi.nlm.nih.gov/pubmed/19250063>
131. Kaddar T, Chien WW, Bertrand Y, Pages MP, Rouault JP, **Salles G**, Ffrench M, Magaud JP. Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. *Leuk Res*. 2009; 33(9):1217-23. <https://www.ncbi.nlm.nih.gov/pubmed/19195700>
132. Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, Gabarre J, Stamatoullas A, Lenoir G, **Salles G**. Pharmacogenetic study in Hodgkin's lymphomas reveals the impact of UGT1A1 polymorphisms on patient's prognosis. *Blood*. 2009, 113:3307-13 <https://www.ncbi.nlm.nih.gov/pubmed/18768784>
133. Ribrag V, Gisselbrecht C, Haioun C, **Salles G**, Golfier JB, Ertault M, Ferme C, Briere J, Brice P, Mounier N. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). *Cancer*. 2009 115:4540-6 <https://www.ncbi.nlm.nih.gov/pubmed/19593797>
134. Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais J-P, **Salles G**, Berger F, Haioun C, Tilly H, Emile J-F, Banham A-H, Mounier N, Gisselbrecht C, Feugier P, Coiffier B, Molina TJ. An Immuno-FISH Index Predicts Survival In Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP: A GELA Study. *J Clin Oncol* 2009 27:5573-9 <https://www.ncbi.nlm.nih.gov/pubmed/19786664>
135. Frecha C, Costa C, Levy C, Nègre D, Russell SJ, Maisner AJ, **Salles G**, Peng K-W, Cosset F-L, and Verhoeyen E. Efficient and stable transduction of resting B-lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp-displaying lentiviral vectors. *Blood*. 2009 Oct 8;114(15):3173-80. <https://www.ncbi.nlm.nih.gov/pubmed/19667401>
136. Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, Van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans

- P, Tirelli U, Leeksa OC, Tomšič R, Feugier P, **Salles G**, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M; for the EORTC-GELA H8 Trial Group. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. *Lancet Oncol*. 2009 10:1160-70. <https://www.ncbi.nlm.nih.gov/pubmed/19828373>
137. Chebel A, Rouault JP, Urbanowicz I, Baseggio L, Chien WW, **Salles G**, Ffrench M. Transcriptional activation of hTERT, the catalytic subunit of telomerase, by NFAT. *J Biol Chem*. 2009 284:35725-34. <https://www.ncbi.nlm.nih.gov/pubmed/19843528>
138. Baseggio L, Traverse-Glehen A, Petinataud F, Callet-Bauchu E, Berger F, Ffrench M, Couris CM, Thieblemont C, Morel D, Coiffier B, **Salles G**, Felman P. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathologic, cytogenetic and molecular study of 24 cases. *Haematologica* 2010; 95:604-12. <https://www.ncbi.nlm.nih.gov/pubmed/20015887>
139. Murga Penas E-M, Callet-Bauchu E, Ye H, Gazzo S, Berger F, Schilling G, Albert-Konetzny N, Vettorazzi E, **Salles G**, Wlodarska I, Du M-Q, Bokemeyer C, Dierlamm J. The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma. *Blood* 2010, 115:2214-9 <https://www.ncbi.nlm.nih.gov/pubmed/19965626>
140. Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoulle D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-Celigny P and **Salles G**. Long Term Follow-up of 536 Newly Diagnosed Follicular Lymphoma Patients in the pre-Rituximab Era: Effect of pre-Treatment Prognostic Variables and Response Quality on Survival. A Study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). *J Clin Oncol*, 2010 28:822-9. <https://www.ncbi.nlm.nih.gov/pubmed/20026809>
141. Larouche J-F, Berger F, Chassagne-Clément C, Ffrench M, Callet-Bauchu E, Sebban C, Ghesquières H, Broussais-Guillaumot F, **Salles G**, Coiffier B. Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-Cell Lymphoma: Clinical Characteristics and Outcome. *J Clin Oncol*, 2010 28(12):2094-100 <https://www.ncbi.nlm.nih.gov/pubmed/20308668>
142. Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Rémy-Martin JP, Callanan M, Traverse-Glehen A, Grandclément C, Garnache-Ottou F, Gressin R, Deconinck E, **Salles G**, Robinet E, Tiberghien P, Borg C, Ferrand C. Identification of an alternative CD20 transcript variant in B cell malignancies coding for a novel protein associated to rituximab resistance. *Blood*. 2010 115:2420-9. <https://www.ncbi.nlm.nih.gov/pubmed/20089966>
143. Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, Michallet AS, Traullé C, **Salles G**, Coiffier B. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. *Leuk Lymphoma*. 2010 Mar;51(3):399-405 <https://www.ncbi.nlm.nih.gov/pubmed/20038227>
144. Falandry C, Fourel G, Galy V, Ristriani T, Horard B, Bensimon E, **Salles G**, Gilson E, Magdinier F. CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregation. *J Biol Chem*. 2010 285:20234-41. <https://www.ncbi.nlm.nih.gov/pubmed/20404330>
145. Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, Tilly H, Bastard C, **Salles GA**, Feugier P, Thieblemont C, Gisselbrecht C, de Reynies A, Coiffier B, Haioun C, Leroy K. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. *Blood*. 2010 116:1092-104. <https://www.ncbi.nlm.nih.gov/pubmed/20435884>

146. Baseggio L, Traverse-Glehen A, Callet-Bauchu E, Morel D, Magaud JP, Berger F, **Salles G**, Felman P. Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL). *Hematol Oncol*. 2011;29(1):47-51.
<https://www.ncbi.nlm.nih.gov/pubmed/20677173>
147. Chien WW, Domenech C, Catallo R, **Salles G**, Ffrench M. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53. *Cell Cycle*. 2010; 9:3286-96. <https://www.ncbi.nlm.nih.gov/pubmed/20703084>
148. Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, **Salles G**, Leblond V, Roussel M, Alakl M, Hermine O, Planche L, Harousseau JL, Fermanand JP. Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed AL amyloidosis: a multicenter phase 1/2 dose escalation study. *Blood*. 2010;116:4777-82
<https://www.ncbi.nlm.nih.gov/pubmed/20724537>
149. **Salles G**, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet* 2011, 377:42-51
<https://www.ncbi.nlm.nih.gov/pubmed/21176949>
150. Augereau A, T'kintdeRoodenbeke C, Simonet T, Bauwens S, Horard B, Callanan M, Leroux D, Jallades L, **Salles G**, Gilson E, Poncet D. Telomeric damage in early stage of Chronic Lymphocytic Leukemia correlates with shelterin dysregulation. *Blood* 2011, 118:1316-22
<https://www.ncbi.nlm.nih.gov/pubmed/21355086>
151. Trotman J, Fournier M, Lamy T, Seymour J-F, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borgh V, **Salles G** PET-CT after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants. *J Clin Oncol* 2011, 29:3194-200 <https://www.ncbi.nlm.nih.gov/pubmed/21747087>
152. Chien WW, Domenech C, Catallo R, Kaddar T, Magaud JP, **Salles G**, Ffrench M. Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway. *Oncogene*. 2011, 30:1880-91
<https://www.ncbi.nlm.nih.gov/pubmed/21170085>
153. **Salles G**, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina TJ, Lee AM, Pfreundschuh M, Horning SJ, Lister TA, Sehn LH, Raemaekers JM, Hagenbeek A, Gascoyne R, Weller E. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. *Blood*, 2011 117:7070-8
<https://www.ncbi.nlm.nih.gov/pubmed/21536860>
154. Le Gouill S, de Guibert S, Planche L, Brice P, Dupuis J, Cartron G, van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, **Salles G**. Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. *Haematologica* 2011, 96:1128-35
<https://www.ncbi.nlm.nih.gov/pubmed/21486862>

155. Baseggio L, Traverse-Glehen A, Berger F, Ffrench M, Jallades L, Morel D, Goedert G, Magaud JP, **Salles G**, Felman P. CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma. *Mod Pathol*. 2011, 24:993-1003
<https://www.ncbi.nlm.nih.gov/pubmed/21499231>
156. Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, **Salles G**, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquieres H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C. Survival impact of rituximab combined with ACVBP and upfront consolidative autotransplantation in high risk diffuse large B-cell lymphoma for GELA. *Haematologica*. 2011, 96:1136-43.
<https://www.ncbi.nlm.nih.gov/pubmed/21546499>
157. Ranchon F, Vantard N, Gouraud A, Schwiertz V, Franchon E, Pham BN, Vial T, You B, Bouafia F, **Salles G**, Rioufol C. Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report - Should the Practice Be Changed? *Chemotherapy*. 2011 57:225-229 . <https://www.ncbi.nlm.nih.gov/pubmed/21597286>
158. Ranchon F, **Salles G**, Spath HM, Schwiertz V, Vantard N, Parat S, Broussais F, You B, Tartas S, Souquet PJ, Dussart C, Falandry C, Henin E, Freyer G, Rioufol C. Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. *BMC Cancer*. 2011; 11(1):478.
<https://www.ncbi.nlm.nih.gov/pubmed/22067636>
159. Vidal L, Gafter-Gvili A, **Salles G**, Dreyling MH, Ghielmini M, Hsu Schmitz SF, Pettengell R, Witzens-Harig M, Shpilberg O. Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. *J Natl Cancer Inst*. 2011; 103(23):1799-806. <https://www.ncbi.nlm.nih.gov/pubmed/22021664>
160. Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont, C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, **Salles G**, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. *Lancet*. 2011; 378(9806):1858-67.
<https://www.ncbi.nlm.nih.gov/pubmed/22118442>
161. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, **Salles G**, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S; for the German PTLD Study Group; the European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. *Lancet Oncol*. 2012 13:196-206
<https://www.ncbi.nlm.nih.gov/pubmed/22173060>
162. Bouteloup M, Verney A, Rachinel N, Callet-Bauchu E, Ffrench M, Coiffier B, Magaud JP, Berger F, **Salles GA**, Traverse-Glehen A. MicroRNA expression profile in splenic marginal zone lymphoma. *Br J Haematol*. 2012 Jan;156(2):279-81
<https://www.ncbi.nlm.nih.gov/pubmed/21902683>
163. Gilis L, Lebras L, Bouafia-Sauvy F, Espinouse D, Felman P, Berger F, **Salles G**, Coiffier B, Michallet AS. Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplantation: a first line strategy for CD4+CD56+ hematodermic neoplasm. *Leuk Lymphoma*. 2012 53(8):1633-7 <https://www.ncbi.nlm.nih.gov/pubmed/22260159>
164. Ranchon F, Moch C, You B, **Salles G**, Schwiertz V, Vantard N, Franchon E, Dussart C, Henin E, Colomban O, Girard P, Freyer G, Rioufol C. Predictors of prescription errors involving anticancer

chemotherapy agents. *Eur J Cancer*. 2012; 48(8):1192-9.
<https://www.ncbi.nlm.nih.gov/pubmed/22285178>

165. Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, Delmer A, **Salles G**, Morschhauser F, Delarue R, Brice P, Bouabdallah R, Casasnovas O, Tilly H, Gaulard P, Haioun C. Targeting intratumoral B-cells with Rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. *Haematologica*. 2012; 97(10):1594-602.
<https://www.ncbi.nlm.nih.gov/pubmed/22371178>
166. **Salles G**, Morschhauser F, Lamy T, Milpied NJ, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. *Blood*. 2012; 119: 5126-5132 <https://www.ncbi.nlm.nih.gov/pubmed/22431570>
167. Chauchet A, Michallet AS, Berger F, Bedgedjian I, Deconinck E, Sebban C, Antal D, Orfeuvre H, Corront B, Petrella T, Hacini M, Bouteloup M, **Salles G**, Coiffier B. Complete remission after first-line radiochemotherapy as predictor of survival in extranodal NK/T cell lymphoma. *J Hematol Oncol*. 2012; 8;5(1):27 <https://www.ncbi.nlm.nih.gov/pubmed/22682004>
168. Valero JG, Cornut-Thibaut A, Jugé R, Debaud AL, Giménez D, Gillet G, Bonnefoy-Bérard N, Salgado J, **Salles G**, Aouacheria A, Kucharczak J. μ -Calpain Conversion of Antiapoptotic Bfl-1 (BCL2A1) into a Prodeath Factor Reveals Two Distinct alpha-Helices Inducing Mitochondria-Mediated Apoptosis. *PLoS One*. 2012; 7(6):e38620.
<https://www.ncbi.nlm.nih.gov/pubmed/22745672>
169. Baseggio L, Geay MO, Gazzo S, Berger F, Traverse-Glehen A, Ffrench M, Hayette S, Callet-Bauchu E, Verney A, Morel D, Jallades L, Magaud JP, **Salles G**, Felman P. In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia. *Br J Haematol*. 2012; 158(4):489-9. <https://www.ncbi.nlm.nih.gov/pubmed/22686190>
170. Colombat P, Brousse N, **Salles G**, Morschhauser F, Brice P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Tilly H, Thieblemont C, Bergougnoux L, Lazreg F, Solal-Celigny P. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. *Ann Oncol*. 2012; 23(9):2380-5.
<https://www.ncbi.nlm.nih.gov/pubmed/22782332>
171. Morschhauser F, Recher C, Milpied N, Gressin R, **Salles G**, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. *Ann Oncol*. 2012, 23(10):2687-95.
<https://www.ncbi.nlm.nih.gov/pubmed/22767588>
172. Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, **Salles G**. Clinical outcome of follicular lymphoma patients receiving chemo-immunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. *Blood*. 2012; 120(13):2650-7 <https://www.ncbi.nlm.nih.gov/pubmed/22885164>
173. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, **Salles G**, Moskowitz CH, Glass B. Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. *J Clin Oncol*. 2012; 30(36):4462-9] <https://www.ncbi.nlm.nih.gov/pubmed/23091101>

174. Hayette S, Thomas X, Jallades L, Chabane K, Charlot C, Tigaud I, Gazzo S, Morisset S, Cornillet-Lefebvre P, Plesa A, Huet S, Renneville A, **Salles G**, Nicolini FE, Magaud JP, Michallet M. High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. *PLoS One*. 2012; 7(12):e51527 <https://www.ncbi.nlm.nih.gov/pubmed/23251566>
175. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, **Salles G**, Haioun C, Meignan M. Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. *J Clin Oncol*. 2012; 30(35):4317-22 <https://www.ncbi.nlm.nih.gov/pubmed/23109699>
176. Ribrag V, Caballero D, Ferme C, Zucca E, Arranz R, Briones J, Gisselbrecht C, **Salles G**, Gianni AM, Gomez H, Kahatt C, Corrado C, Szyldergemajn S, Extremera S, de Miguel B, Cullell-Young M, Cavalli F. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. *Haematologica*. 2013; 98(3):357-63. <https://www.ncbi.nlm.nih.gov/pubmed/23065525>
177. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, **Salles G**, Van Hoof A, Casasnovas R-O, Brousse N, Lefrere F, Hermine O. CHOP-DHAP plus Rituximab and Autologous Sct in Mantle Cell Lymphoma: A Phase II Study from the GEAL. *Blood* 2013; 121(1):48-53 <https://www.ncbi.nlm.nih.gov/pubmed/22718839>
178. Tilly H, Morschhauser F, **Salles G**, Casasnovas RO, Feugier P, Molina TJ, Jardin F, Terriou L, Haioun C, Coiffier B. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. *Leukemia*. 2013 27(1):252-5 <https://www.ncbi.nlm.nih.gov/pubmed/22733106>
179. Lefrère F, Bastit-Barrau D, Hequet O, Bourin P, Mathieu-Nafissi S, Bohbot A, Tilly H, **Salles G**, Fermé C, Lapierre V, Fornecker L, Micléa JM, Isebaert L, Bologna S, Fitoussi O, Mounier N, Haioun C. Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients. *Transfusion*. 2013; 53(1):115-22 <https://www.ncbi.nlm.nih.gov/pubmed/22563760>
180. Jardin F, Delfau-Larue MH, Molina TJ, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Jais JP, Figeac M, Leroy K, Mareschal S, **Salles GA**, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Haioun C, Tilly H. Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2013 54(9):1898-907. <https://www.ncbi.nlm.nih.gov/pubmed/23327290>
181. Jantunen E, Boumendil A, Finel H, Luan JJ, Johnson P, Rambaldi A, Haynes A, Duchosal MA, Bethge W, Biron P, Carlson K, Craddock C, Rudin C, Finke J, **Salles G**, Kroschinsky F, Sureda A, Dreger P. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. *Blood*. 2013 ;121(13):2529-32 <https://www.ncbi.nlm.nih.gov/pubmed/23361910>
182. Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, **Salles G**, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A. 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial. *J Clin Oncol*. 2013 31(16):1977-83 <https://www.ncbi.nlm.nih.gov/pubmed/23547079>

183. Delarue R, Tilly H, Mounier N, Petrella T, **Salles G**, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. *Lancet Oncol.* 2013; 14(6):525-33
<https://www.ncbi.nlm.nih.gov/pubmed/23578722>
184. Traverse-Glehen A, Bachy E, Baseggio L, Callet-Bauchu E, Gazzo S, Verney A, Hayette S, Jallades L, Ffrench M, **Salles G**, Coiffier B, Felman P, Berger F. Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases. *Histopathology.* 2013 62(6):876-93
<https://www.ncbi.nlm.nih.gov/pubmed/23611359>
185. Zimmermann H, Choquet S, Moore J, **Salles G**, Morschhauser F, Lamy T, Jaccard A, Horst HA, Leithäuser M, Dührsen U, Reinke P, Lebranchu Y, Neuhaus R, Lehmkuhl H, Tarella C, Schlattmann P, Riess H, Leblond V, Trappe RU. Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLTD-1 trial. *Leukemia.* 2013 27(10):2102-5. <https://www.ncbi.nlm.nih.gov/pubmed/23584565>
186. Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, **Salles G**; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. *Haematologica.* 2013 98(7):1107-14. <https://www.ncbi.nlm.nih.gov/pubmed/23645690>
187. Michallet AS, Lebras L, Bauwens D, Bouafia-Sauvy F, Berger F, Tychy-Pinel C, D Hombres A, **Salles G**, Coiffier B. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? *J Hematol Oncol.* 2013 6(1):45.
<https://www.ncbi.nlm.nih.gov/pubmed/23816219>
188. Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, López-Guillermo A, Mackinnon S, Marcus RE, **Salles G**, Schouten HC, Sureda A, Dreger P. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. *Haematologica.* 2013 98(7):1014-21
<https://www.ncbi.nlm.nih.gov/pubmed/23813647>
189. Mounier N, El-Gnaoui T, Tilly H, Canioni D, Sebban C, Casasnovas RO, Delarue R, Sonet A, Beaussart P, Petrella T, Castaigne S, Bologna S, **Salles G**, Rahmouni A, Gaulard P, Haioun C. Rituximab plus gemcitabine and oxaliplatin in refractory/relapsed patients with diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. *Haematologica.* 2013 98(11):1726-31 <https://www.ncbi.nlm.nih.gov/pubmed/23753028>
190. Radford J, Davies A, Cartron G, Morschhauser F, **Salles G**, Marcus R, Wenger M, Lei G, Wassner-Fritsch E, Vitolo U. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). *Blood.* 2013;122(7):1137-43
<https://www.ncbi.nlm.nih.gov/pubmed/23843495>
191. Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, **Salles GA**. Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. *J Clin Oncol.* 2013; 31(23):2912-9 <https://www.ncbi.nlm.nih.gov/pubmed/23835718>
192. **Salles GA**, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G. Obinutuzumab (GA101) in Patients With

Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study. *J Clin Oncol*. 2013 ;31(23):2920-6 <https://www.ncbi.nlm.nih.gov/pubmed/23835715>

193. Ghesquieres H, Maurer MJ, Casasnovas O, Ansell SM, Larrabee BR, Lech-Maranda, E, Novak AJ, Borrel AI, Slager SL, Brice P, Allmer C, Brion A, Ziesmer SC, Morschhauser F, Habermann TM, Gaillard I, Link BK, Stamatoullas A, Ferme C, Dogan A, Macon WR, Audouin J, Cerhan JR, **Salles G**. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. *Cytokine*. 2013 64(2):523-531. <https://www.ncbi.nlm.nih.gov/pubmed/24008079>
194. Trebouet A, Marchand T, Lemal R, Gyan E, Broussais-Guillaumot F, Guillermin Y, Monjanel H, **Salles G**, Le Gouill S, Godmer P, Fruchart C, Damaj G, Feugier P, Thieblemont C, Maynadié M, Monnereau A, Troussard X, Rossille D, Lamy T, Houot R. Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. *Ann Oncol*. 2013 Oct;24(10):2612-8. <https://www.ncbi.nlm.nih.gov/pubmed/23970017>
195. Michallet AS, Cazin B, Bouvet E, Oberic L, Schlaifer D, Mosser L, **Salles G**, Coiffier B, Laurent G, Ysebaert L. First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis. *J Geriatr Oncol*. 2013 Apr;4(2):141-7. <https://www.ncbi.nlm.nih.gov/pubmed/24071539>
196. Ricard F, Giammarile F, Tychyj-Pinel C, Houzard C, Decullier E, Chateau F, Manichon AF, Orliaguet I, Michallet AS, **Salles G**, Valette PJ, Réty F. PET-CT and diagnostic CT: The synergy of metabolic and morphological data in onco-haematology. *Diagn Interv Imaging*. 2013 Sep 3. doi:pii: S2211-5684(13)00234-9. <https://www.ncbi.nlm.nih.gov/pubmed/24012287>
197. Ranchon F, You B, **Salles G**, Vantard N, Schwiertz V, Gourc C, Gauthier N, Guédât MG, Souquet PJ, Freyer G, Trillet-Lenoir V, Rioufol C. Improving cancer patient care with combined medication error reviews and morbidity and mortality conferences. *Chemotherapy*. 2013;59(5):330-7. <https://www.ncbi.nlm.nih.gov/pubmed/24801809>
198. Lenglet J, Traullé C, Mounier N, Benet C, Munoz-Bongrand N, Amarin S, Noguera ME, Traverse-Glehen A, Ffrench M, Baseggio L, Felman P, Callet-Bauchu E, Brice P, Berger F, **Salles G**, Brière J, Coiffier B, Thieblemont C. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. *Leuk Lymphoma*. 2014 Aug;55(8):1854-60. <https://www.ncbi.nlm.nih.gov/pubmed/24206091>
199. Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, **Salles G**, Tilly H, Cerhan JR. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. *J Clin Oncol*. 2014 Apr 1;32(10):1066-73. <https://www.ncbi.nlm.nih.gov/pubmed/24550425>
200. Sander B, de Jong D, Rosenwald A, Xie W, Balagué O, Calaminici M, Carreras J, Gaulard P, Gribben J, Hagenbeek A, Kersten MJ, Molina TJ, Lee A, Montes-Moreno S, Ott G, Raemaekers J, **Salles G**, Sehn L, Thorns C, Wahlin BE, Gascoyne RD, Weller E. The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. *Haematologica*. 2014;99(4):715-25 <https://www.ncbi.nlm.nih.gov/pubmed/24510338>
201. Tychyj-Pinel C, Ricard F, Fulham M, Fournier M, Meignan M, Lamy T, Vera P, **Salles G**, Trotman J. Pet/Ct Assessment In Follicular Lymphoma Using Standardized Criteria: Central Review In The Prima Study. *Eur J Nucl Med Mol Imaging*. 2014; 41(3):408-15 <https://www.ncbi.nlm.nih.gov/pubmed/24435770>

202. Gilis L, Morisset S, Billaud G, Ducastelle-Leprêtre S, Labussière-Wallet H, Nicolini FE, Barraco F, Detrait M, Thomas X, Tedone N, Sobh M, Chidiac C, Ferry T, **Salles G**, Michallet M, Ader F. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2014 ;49(5):664-70 <https://www.ncbi.nlm.nih.gov/pubmed/24488049>
203. Hequet O, Le QH, Rodriguez J, Dubost P, Revesz D, Clerc A, Rigal D, **Salles G**, Coiffier B. Development of model for analysing respective collections of intended hematopoietic stem cells and harvests of unintended mature cells in apheresis for autologous hematopoietic stem cell collection. *Transfus Apher Sci.* 2014 Jan 2. pii: S1473-0502(13)00374-1. <https://www.ncbi.nlm.nih.gov/pubmed/24462181>
204. Sarkozy C, Baseggio L, Feugier P, Callet-Bauchu E, Karlin L, Seymour JF, Lebras L, Michallet AS, Offner F, Dumas O, Traverse-Glehen A, Ffrench M, Lopez-Guillermo A, Berger F, Coiffier B, Felman P, **Salles G**. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. *Br J Haematol.* 2014 Mar;164(5):659-67 <https://www.ncbi.nlm.nih.gov/pubmed/24274024>
205. Rioufol C, Ranchon F, Schwiertz V, Vantard N, Joue E, Gourc C, Gauthier N, Guedat MG, **Salles G**, Souquet PJ, Favier B, Gilles L, Freyer G, You B, Trillet-Lenoir V, Guitton J. Administration of anticancer drugs: exposure in hospital nurses. *Clin Ther.* 2014 Mar 1;36(3):401-7 <https://www.ncbi.nlm.nih.gov/pubmed/24612942>
206. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, **Salles GA**. PI3K δ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. *N Engl J Med.* 2014 370(11):1008-18 <https://www.ncbi.nlm.nih.gov/pubmed/24450858>
207. Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P, Jouve N, Palli D, Pala V, Tumino R, Panico S, Sacerdote C, Quiros JR, González C, Sanchez MJ, Dorronsoro M, Navarro C, Barricarte A, Tjonneland A, Olsen A, Overvad K, Canzian F, Kaaks R, Boeing H, Drogan D, Nieters A, Clavel F, Trichopoulou A, Trichopoulos D, Lagiou P, Bueno-De-Mesquita B, Peeters P, Vermeulen R, Hallmans G, Melin B, Borgquist S, Carlson J, Lund E, Weiderpass E, Khaw K-T, Wareham N, Key T, Travis R, Ferrari P, Romieu I, Riboli E, **Salles G**, Vineis P, Nadel B. T(14;18) Translocation: A Predictive Blood Biomarker For Follicular Lymphoma. *J Clin Oncol.* 2014, 32(13):1347-55 <https://www.ncbi.nlm.nih.gov/pubmed/24687831>
208. Sarkozy C, Seymour JF, Ferme C, Caballero D, Ghesquieres H, Leppa S, Delarue R, Pedersen LM, Mounier C, Gomes Da Silva M, Chassagne-Clement C, Maetevoet M, **Salles G**. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. *Blood*, 2014 123(17):2740-2. <https://www.ncbi.nlm.nih.gov/pubmed/24764560>
209. Chien W-W, Allas S, Rachinel N, Sahakian P, Julien M, Le Beux C, Lacroix C-E, Aribat T, **Salles G**. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant *Erwinia chrysanthemi*-derived L-asparaginase. *Invest New Drugs*, 2014 ;32(5):795-805. <https://www.ncbi.nlm.nih.gov/pubmed/24829072>
210. Cerhan JR, Berndt SI, Vijai J, Ghesquières H, McKay J, Wang SS, Wang Z, Yeager M, Conde L, de Bakker PI, Nieters A, Cox D, Burdett L, Monnereau A, Flowers CR, De Roos AJ, Brooks-Wilson AR, Lan Q, Severi G, Melbye M, Gu J, Jackson RD, Kane E, Teras LR, Purdue MP, Vajdic CM, Spinelli JJ, Giles GG, Albanes D, Kelly RS, Zucca M, Bertrand KA, Zeleniuch-Jacquotte A, Lawrence C, Hutchinson A, Zhi D, Habermann TM, Link BK, Novak AJ, Dogan A, Asmann YW, Liebow M, Thompson CA, Ansell SM, Witzig TE, Weiner GJ, Veron AS, Zelenika D, Tilly H,

Haioun C, Molina TJ, Hjalgrim H, Glimelius B, Adami HO, Bracci PM, Riby J, Smith MT, Holly EA, Cozen W, Hartge P, Morton LM, Severson RK, Tinker LF, North KE, Becker N, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, Lightfoot T, Crouch S, Smith A, Roman E, Diver WR, Offit K, Zelenetz A, Klein RJ, Villano DJ, Zheng T, Zhang Y, Holford TR, Krickler A, Turner J, Southey MC, Clavel J, Virtamo J, Weinstein S, Riboli E, Vineis P, Kaaks R, Trichopoulos D, Vermeulen RC, Boeing H, Tjonneland A, Angelucci E, Di Lollo S, Rais M, Birmann BM, Laden F, Giovannucci E, Kraft P, Huang J, Ma B, Ye Y, Chiu BC, Sampson J, Liang L, Park JH, Chung CC, Weisenburger DD, Chatterjee N, Fraumeni JF Jr, Slager SL, Wu X*, de Sanjose S*, Smedby KE*, **Salles G***, Skibola CF*, Rothman N*, Chanock SJ*. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. *Nat Genet.* 2014 Nov;46(11):1233-8. <https://www.ncbi.nlm.nih.gov/pubmed/25261932>

(* these authors jointly directed the work)

211. Xerri L, Bachy E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuillères P, Charlotte F, Brousse N, Rousselet MC, Foussard C, Brice P, Feugier P, Morschhauser F, Sonet A, Olive D, **Salles G**; a LYSA study. Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. *Hum Pathol.* 2014 45(10):2085-93. <https://www.ncbi.nlm.nih.gov/pubmed/25149549>
212. Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, **Salles GA**. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. *Hematology.* 2015 20(3):129-36 <https://www.ncbi.nlm.nih.gov/pubmed/25029908>
213. Brisou G, Verney A, Wenner T, Baseggio L, Felman P, Callet-Bauchu E, Coiffier B, Berger F, **Salles G**, Traverse-Glehen A. A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders. *Haematologica.* 2014 Oct;99(10):e197-8. <https://www.ncbi.nlm.nih.gov/pubmed/24997147>
214. Skibola CF, Berndt SI, Vijai J, Conde L, Wang Z, Yeager M, de Bakker PI, Birmann BM, Vajdic CM, Foo JN, Bracci PM, Vermeulen RC, Slager SL, de Sanjose S, Wang SS, Linet MS, **Salles G**, Lan Q, Severi G, Hjalgrim H, Lightfoot T, Melbye M, Gu J, Ghesquières H, Link BK, Morton LM, Holly EA, Smith A, Tinker LF, Teras LR, Krickler A, Becker N, Purdue MP, Spinelli JJ, Zhang Y, Giles GG, Vineis P, Monnereau A, Bertrand KA, Albanes D, Zeleniuch-Jacquotte A, Gabbas A, Chung CC, Burdett L, Hutchinson A, Lawrence C, Montalvan R, Liang L, Huang J, Ma B, Liu J, Adami HO, Glimelius B, Ye Y, Nowakowski GS, Dogan A, Thompson CA, Habermann TM, Novak AJ, Liebow M, Witzig TE, Weiner GJ, Schenk M, Hartge P, De Roos AJ, Cozen W, Zhi D, Akers NK, Riby J, Smith MT, Lacher M, Villano DJ, Maria A, Roman E, Kane E, Jackson RD, North KE, Diver WR, Turner J, Armstrong BK, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, McKay J, Brooks-Wilson AR, Zheng T, Holford TR, Chamosa S, Kaaks R, Kelly RS, Ohlsson B, Travis RC, Weiderpass E, Clavel J, Giovannucci E, Kraft P, Virtamo J, Mazza P, Cocco P, Ennas MG, Chiu BC, Fraumeni JF Jr, Nieters A, Offit K, Wu X, Cerhan JR, Smedby KE, Chanock SJ, Rothman N. Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. *Am J Hum Genet.* 2014 Oct 2;95(4):462-471 <https://www.ncbi.nlm.nih.gov/pubmed/25279986>
215. Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viillard JF, Cheze S, Graveleau J, Slama B, Audia S, Ebbo M, Le Guenno G, Cliquennois M, **Salles G**, Bonmati C, Teillet F, Galicier L, Hot A, Lambotte O, Lefrère F, Sacko S, Kilendo Kengue D, Bierling P, Roudot-Thoraval F, Michel M, Godeau B. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. *Blood.* 2014 124(22):3228-36. <https://www.ncbi.nlm.nih.gov/pubmed/25293768>

216. Lefèvre G, Copin MC, Staumont-Sallé D, Avenel-Audran M, Aubert H, Taieb A, **Salles G**, Maisonneuve H, Ghomari K, Ackerman F, Legrand F, Baruchel A, Launay D, Terriou L, Leclech C, Khouatra C, Morati-Hafsaoui C, Labalette M, Borie R, Cotton F, Gouellec NL, Morschhauser F, Trauet J, Roche-Lestienne C, Capron M, Hatron PY, Prin L, Kahn JE; French Eosinophil Network. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. *Medicine (Baltimore)*. 2014 Oct;93(17):255-66. <https://www.ncbi.nlm.nih.gov/pubmed/25398061>
217. Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, Marcheselli L, Berriolo-Riedinger A, Franceschetto A, Julian A, Ricard F, Guerra L, Haioun C, Biasoli I, Tilly H, Federico M, **Salles G**, Meignan M. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. *Lancet Haematol*. 2014 Oct;1(1):e17-27. <https://www.ncbi.nlm.nih.gov/pubmed/27030064>
218. Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, **Salles G**, Fabiani B, Morschhauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H. Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. *J Clin Oncol*. 2014 Dec 10;32(35):3996-4003. <https://www.ncbi.nlm.nih.gov/pubmed/25385729>
219. Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat MG, He S, Kiouris E, Alloux C, You B, Souquet PJ, Freyer G, **Salles G**, Trillet-Lenoir V, Rioufol C. EPICC study: evaluation of pharmaceutical intervention in cancer care. *J Clin Pharm Ther*. 2015 Apr;40(2):196-203. <https://www.ncbi.nlm.nih.gov/pubmed/25594148>
220. Jordheim LP, Ribrag V, Ghesquieres H, Pallardy S, Delarue R, Tilly H, Haioun C, Jardin F, Demangel D, **Salles GA**, Dumontet C. Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non Hodgkin lymphoma. *Haematologica*. 2015 May;100(5):e204-6. <https://www.ncbi.nlm.nih.gov/pubmed/25637052>
221. Chien WW, Le Beux C, Rachinel N, Julien M, Lacroix CE, Allas S, Sahakian P, Cornut-Thibaut A, Lionnard L, Kucharczak J, Aouacheria A, Abribat T, **Salles G**. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. *Sci Rep*. 2015 Jan 28;5:8068. <https://www.ncbi.nlm.nih.gov/pubmed/25626693>
222. Chien WW, Catallo R, Chebel A, Baranger L, Thomas X, Béné MC, Gerland LM, Schmidt A, Beldjord K, Klein N, Escoffre-Barbe M, Leguay T, Huguet F, Larosa F, Hayette S, Plesa A, Ifrah N, Dombret H, **Salles G**, Chassevent A, Ffrench M. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. *Leuk Res*. 2015 Jan 25. pii: S0145-2126(15)00025-9. <https://www.ncbi.nlm.nih.gov/pubmed/25675863>
223. Lefèvre G, Copin MC, Roumier C, Aubert H, Avenel-Audran M, Gardel N, Poulain S, Staumont-Salle' D, Seneschal J, **Salles G**, Ghomari K, Terriou L, Leclech C, Morati-Hafsaoui C, Morschhauser F, Lambotte O, Ackerman F, Trauet J, Geffroy S, Dumezy F, Capron M, Roche-Lestienne C, Taieb A, Hatron PY, Dubucquoi S, Hachulla E, Prin L, Labalette M, Launay D, Preudhomme C, Kahn JE. CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. *Haematologica*. 2015 Aug;100(8):1086-95. <https://www.ncbi.nlm.nih.gov/pubmed/25682606>

224. Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, **Salles GA**, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. *Leukemia*. 2015 29(7):1578-86.
<https://www.ncbi.nlm.nih.gov/pubmed/25708834>
225. Kelly JL, **Salles G**, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. *J Clin Oncol*. 2015 May 1;33(13):1482-90.
<https://www.ncbi.nlm.nih.gov/pubmed/25823738>
226. Michallet AS, Guillermin Y, Deau B, Lebras L, Harel S, Amarin S, Reynes C, **Salles G**, Subtil F, Brice P. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and Brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. *Haematologica*. 2015 Jul;100(7):e269-71. <https://www.ncbi.nlm.nih.gov/pubmed/25840598>
227. Delfau-Larue MH, Klapper W, Berger F, Jardin F, Briere J, **Salles G**, Casasnovas O, Feugier P, Haioun C, Ribrag V, Thieblemont C, Unterhalt M, Dreyling M, Macintyre E, Pott C, Hermine O, Hoster E; European Mantle Cell Lymphoma Network. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. *Blood*. 2015 Jul 30;126(5):604-11. <https://www.ncbi.nlm.nih.gov/pubmed/26022239>
228. Palanca-Wessels MC, Czuczman M, **Salles G**, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. *Lancet Oncol*. 2015 Jun;16(6):704-15.
<https://www.ncbi.nlm.nih.gov/pubmed/25925619>
229. Mareschal S, Ruminy P, Bagacean C, Marchand V, Cornic M, Jais JP, Figeac M, Picquenot JM, Molina TJ, Fest T, **Salles G**, Haioun C, Leroy K, Tilly H, Jardin F. Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. *J Mol Diagn*. 2015 Apr 9. pii: S1525-1578(15)00046-X.
<https://www.ncbi.nlm.nih.gov/pubmed/25891505>
230. Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, Canioni D, Farinha P, Boussetta S, Moccia AA, Brice P, Chavez EA, Kyle AH, Scott DW, Sanders A, Fabiani B, Slack G, Minchinton AI, Haioun C, Connors JM, Sehn L, Steidl C, Gascoyne RD, **Salles G**. The prognostic impact of CD163-positive macrophages in follicular lymphoma: A study from the BC Cancer Agency and the LYmphoma Study Association. *Clin Cancer Res*. 2015 Aug 1;21(15):3428-35.
<https://www.ncbi.nlm.nih.gov/pubmed/25869385>
231. Fouquet G, Guidez S, Petillon MO, Louni C, Ohyba B, Dib M, Poulain S, Herbaux C, Martin A, Thielemans B, Brice P, Choquet S, Bakala J, Bories C, Demarquette H, Nudel M, Tournilhac O, Arnulf B, LeGouill S, Morel P, Banos A, Karlin L, **Salles G**, Leblond V, Leleu X. Lenalidomide is safe and active in Waldenström macroglobulinemia. *Am J Hematol*. 2015 Nov;90(11):1055-9.
<https://www.ncbi.nlm.nih.gov/pubmed/26284823>
232. Cannas G, Fattoum J, Raba M, Dolange H, Barday G, François M, Elhamri M, **Salles G**, Thomas X. Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are

- associated with poorer outcomes in adult acute myeloid leukemia. *Ann Hematol*. 2015 Nov;94(11):1797-806. <https://www.ncbi.nlm.nih.gov/pubmed/26202609>
233. Trappe RU, Choquet S, Dierickx D, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Tarella C, Shpilberg O, Sender M, **Salles G**, Morschhauser F, Jaccard A, Lamy T, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Leithäuser M, Schlattmann P, Anagnostopoulos I, Raphael M, Riess H, Leblond V, Oertel S; German PTLD Study Group and the European PTLD Network. International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLD: Clues From the PTLD-1 Trial. *Am J Transplant*. 2015 Apr;15(4):1091-100. <https://www.ncbi.nlm.nih.gov/pubmed/25736912>
234. Copie-Bergman C, Cuillière-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, **Salles G**, Parrens M, Belhadj K, Fabiani B, Recher C, Petrella T, Ketterer N, Peyrade F, Haioun C, Nagel I, Siebert R, Jardin F, Leroy K, Jais JP, Tilly H, Molina TJ, Gaulard P. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. *Blood*. 2015 26;126(22):2466-74 <https://www.ncbi.nlm.nih.gov/pubmed/26373676>
235. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, **Salles G**, Moskowitz CH, Glass B, Gisselbrecht C. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. *Bone Marrow Transplant*. 2016 51(1):51-7. <https://www.ncbi.nlm.nih.gov/pubmed/26367239>
236. Heiblig M, Elhamri M, Nicolini FE, Wattel E, Michallet M, **Salles G**, Thomas X. Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study. *Clin Lymphoma Myeloma Leuk*. 2015 Jun;15 Suppl:S7-S13. <https://www.ncbi.nlm.nih.gov/pubmed/26297282>
237. You B, **Salles G**, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the Lymphoma Study Association (LYSA). *Cancer Chemother Pharmacol*. 2015 Nov;76(5):939-48. <https://www.ncbi.nlm.nih.gov/pubmed/26391155>
238. Michallet AS, Sesques P, Rabe KG, Itti E, Tordot J, Tychyj-Pinel C, Baseggio L, Subtil F, **Salles G**, Dupuis JM, Conte MJ. An 18F-FDG-PET maximum standardized uptake value >10 represents a novel valid marker for discerning Richter's Syndrome. *Leuk Lymphoma*. 2016;57(6):1474-7. <https://www.ncbi.nlm.nih.gov/pubmed/26402256>
239. Mestrallet F, Sujobert P, Sarkozy C, Traverse-Glehen A, Callet-Bauchu E, Magaud JP, **Salles G**, Baseggio L. CD180 overexpression in follicular lymphoma is restricted to the lymph node compartment. *Cytometry B Clin Cytom*. 2016 Sep;90(5):433-9 <https://www.ncbi.nlm.nih.gov/pubmed/26482097>
240. Ghesquieres H, Slager SL, Jardin F, Veron AS, Asmann YW, Maurer MJ, Fest T, Habermann TM, Bene MC, Novak AJ, Mareschal S, Haioun C, Lamy T, Ansell SM, Tilly H, Witzig TE, Weiner GJ, Feldman AL, Dogan A, Cunningham JM, Olszold CL, Molina TJ, Link BK, Milpied N, Cox DG, **Salles GA**, Cerhan JR. Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. *J Clin Oncol*. 2015 20;33(33):3930-7. <https://www.ncbi.nlm.nih.gov/pubmed/26460308>
241. Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E, Gribben JG, Hallek M, **Salles G**, Cartron G. Cytokine release in patients with

- CLL treated with obinutuzumab and possible relationship with infusion related reactions. *Blood*. 2015 10;126(24):2646-9. <https://www.ncbi.nlm.nih.gov/pubmed/26447188>
242. Hoster E, Geisler CH, Doorduyn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, **Salles G**, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Råty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O. Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. *Leukemia*. 2016;30(6):1428-30
<https://www.ncbi.nlm.nih.gov/pubmed/26598017>
243. Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, **Salles G**, Habermann TM, Tilly H, Cerhan JR. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. *Am J Hematol*. 2016 Feb;91(2):179-84.
<https://www.ncbi.nlm.nih.gov/pubmed/26492520>
244. Mareschal S, Dubois S, Viailly PJ, Bertrand P, Bohers E, Maingonnat C, Jaïs JP, Tesson B, Ruminy P, Peyrouze P, Copie-Bergman C, Fest T, Jo Molina T, Haioun C, **Salles G**, Tilly H, Lecroq T, Leroy K, Jardin F. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. *Genes Chromosomes Cancer*. 2016 Mar;55(3):251-67. <https://www.ncbi.nlm.nih.gov/pubmed/26608593>
245. Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, Scime R, Kobbe G, Ferrara F, Delmer A, Sayer H, Amorim S, Bouabdallah R, Finke J, **Salles G**, Yakoub-Agha I, Faber E, Nicolas-Virelizier E, Facchini L, Vallisa D, Zuffa E, Sureda A, Dreger P. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. *Bone Marrow Transplant*. 2016 Feb;51(2):212-8. <https://www.ncbi.nlm.nih.gov/pubmed/26569093>
246. Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, **Salles G**. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. *Blood*. 2016 Jan 28;127(4):411-9. <https://www.ncbi.nlm.nih.gov/pubmed/26542378>
247. Fleury I, Chevret S, Pfreundschuh M, **Salles G**, Coiffier B, van Oers MH, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. *Ann Oncol*. 2016 Mar;27(3):390-7. <https://www.ncbi.nlm.nih.gov/pubmed/26681685>
248. Cartron G, Hourcade-Potelleret F, Morschhauser F, **Salles G**, Wenger M, Truppel-Hartmann A, Carlile DJ. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. *Haematologica*. 2016 Feb;101(2):226-34.
<https://www.ncbi.nlm.nih.gov/pubmed/26659915>
249. Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, **Salles G**, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. *J Clin Oncol*. 2016 Feb 20;34(6):572-80.
<https://www.ncbi.nlm.nih.gov/pubmed/26644537>
250. Bachy E, Urb M, Chandra S, Robinot R, Bricard G, de Bernard S, Traverse-Glehen A, Gazzo S, Blond O, Khurana A, Baseggio L, Heavican T, Ffrench M, Crispatsu G, Mondière P, Schrader A,

- Taillardet M, Thaunat O, Martin N, Dalle S, Le Garff-Tavernier M, **Salles G**, Lachuer J, Hermine O, Asnafi V, Roussel M, Lamy T, Herling M, Iqbal J, Buffat L, Marche PN, Gaulard P, Kronenberg M, Defrance T, Genestier L. CD1d-restricted peripheral T cell lymphoma in mice and humans. *J Exp Med*. 2016 ;213(5):841-57 <https://www.ncbi.nlm.nih.gov/pubmed/27069116>
251. Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, **Salles G**, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. *Lancet Haematol*. 2016 Apr;3(4):e196-204. <https://www.ncbi.nlm.nih.gov/pubmed/27063978>
252. Machiela MJ, Lan Q, Slager SL, Vermeulen RC, Teras LR, Camp NJ, Cerhan JR, Spinelli JJ, Wang SS, Nieters A, Vijai J, Yeager M, Wang Z, Ghesquières H, McKay J, Conde L, de Bakker PI, Cox DG, Burdett L, Monnereau A, Flowers CR, De Roos AJ, Brooks-Wilson AR, Giles GG, Melbye M, Gu J, Jackson RD, Kane E, Purdue MP, Vajdic CM, Albanes D, Kelly RS, Zucca M, Bertrand KA, Zeleniuch-Jacquotte A, Lawrence C, Hutchinson A, Zhi D, Habermann TM, Link BK, Novak AJ, Dogan A, Asmann YW, Liebow M, Thompson CA, Ansell SM, Witzig TE, Tilly H, Haioun C, Molina TJ, Hjalgrim H, Glimelius B, Adami HO, Roos G, Bracci PM, Riby J, Smith MT, Holly EA, Cozen W, Hartge P, Morton LM, Severson RK, Tinker LF, North KE, Becker N, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, Lightfoot T, Crouch S, Smith A, Roman E, Diver WR, Offit K, Zelenetz A, Klein RJ, Villano DJ, Zheng T, Zhang Y, Holford TR, Turner J, Southey MC, Clavel J, Virtamo J, Weinstein S, Riboli E, Vineis P, Kaaks R, Boeing H, Tjønneland A, Angelucci E, Di Lollo S, Rais M, De Vivo I, Giovannucci E, Kraft P, Huang J, Ma B, Ye Y, Chiu BC, Liang L, Park JH, Chung CC, Weisenburger DD, Fraumeni JF Jr, **Salles G**, Glenn M, Cannon-Albright L, Curtin K, Wu X, Smedby KE, de Sanjose S, Skibola CF, Berndt SI, Birmann BM, Chanock SJ, Rothman N. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. *Hum Mol Genet*. 2016 Apr 15;25(8):1663-76. <https://www.ncbi.nlm.nih.gov/pubmed/27008888>
253. Houot R, Soussain C, Tilly H, Haioun C, Thieblemont C, Casasnovas O, Bouabdallah K, Morschhauser F, Le Gouill S, **Salles GA**, Hoang-Xuan K, Choquet S, Marchand T, Laurent C, Pangault C, Lamy T. Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. *Ann Oncol*. 2016 ;27(7):1349-50. <https://www.ncbi.nlm.nih.gov/pubmed/27002105>
254. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, **Salles GA**, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. *Blood*. 2016 19;127(20):2375-90. <https://www.ncbi.nlm.nih.gov/pubmed/26980727>
255. Philippe M, Ranchon F, Gilis L, Schwiertz V, Vantard N, Ader F, Labussiere-Wallet H, Thomas X, Nicolini FE, Wattel E, Ducastelle-Leprêtre S, Barraco F, Lebras L, **Salles G**, Michallet M, Rioufol C. Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2016 Apr;22(4):723-30. <https://www.ncbi.nlm.nih.gov/pubmed/26718666>
256. Medves S, Auchter M, Chambeau L, Gazzo S, Poncet D, Grangier B, Verney A, Moussay E, Ammerlaan W, Brisou G, Morjani H, Géli V, Palissot V, Berchem G, **Salles G**, Wenner T. A high rate of telomeric sister chromatid exchange occurs in chronic lymphocytic leukaemia B-cells. *Br J Haematol*. 2016 ;174(1):57-70 <https://www.ncbi.nlm.nih.gov/pubmed/26970083>
257. Broutier L, Creveaux M, Vial J, Tortereau A, Delcros JG, Chazot G, McCarron MJ, Léon S, Pangault C, Gadot N, Colombe A, Boulland ML, Blachier J, Marie JC, Traverse-Glehen A, Donzé

- O, Chassagne-Clément C, **Salles G**, Tarte K, Mehlen P, Castets M. Targeting netrin-1/DCC interaction in diffuse large B-cell and mantle cell lymphomas. *EMBO Mol Med*. 2016 Jan 31;8(2):96-104. <https://www.ncbi.nlm.nih.gov/pubmed/26882243>
258. Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, Maingonnat C, Jais JP, Peyrouze P, Figeac M, Molina TJ, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Briere J, Petrella T, Canioni D, Fabiani B, Coiffier B, Delarue R, Peyrade F, Bosly A, Andre M, Ketterer N, **Salles G**, Tilly H, Leroy K, Jardin F. Next Generation Sequencing in Diffuse Large B Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. *Clin Cancer Res*. 2016 15;22(12):2919-28. <https://www.ncbi.nlm.nih.gov/pubmed/26819451>
259. Bachy E, Estell JA, Van de Neste E, Bouabdallah R, Bargay J, Delmer A, Gelas-Dore B, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Lamy T, Dartigues P, Francis Seymour J, **Salles G**. Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. *Am J Hematol*. 2016 Jun;91(4):410-5. <https://www.ncbi.nlm.nih.gov/pubmed/26799234>
260. Heiblig M, Elhamri M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Michallet M, Nicolini F, Plesa C, Wattel E, **Salles G**, Thomas X. Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience. *Mediterr J Hematol Infect Dis*. 2016 Jan 1;8(1):e2016009. <https://www.ncbi.nlm.nih.gov/pubmed/26740870>
261. Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, Deau-Fischer B, Bouabdallah R, Sebban C, **Salles G**, Brice P. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. *Haematologica*. 2016 Apr;101(4):474-81. <https://www.ncbi.nlm.nih.gov/pubmed/26721893>
262. Conrad A, Le Maréchal M, Dupont D, Ducastelle-Leprêtre S, Balsat M, Labussière-Wallet H, Barraco F, Nicolini FE, Thomas X, Gilis L, Chidiac C, Ferry T, Wallet F, Rabodonirina M, **Salles G**, Michallet M, Ader F; Lyon HEMINF studyGroup. A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication. *Clin Microbiol Infect*. 2016 May 9. pii: S1198-743X(16)30122-7. <https://www.ncbi.nlm.nih.gov/pubmed/27172809>
263. Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Gouill SL, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, **Salles G**. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2016 ;387(10036):2402-11. <https://www.ncbi.nlm.nih.gov/pubmed/27080498>
264. Mahévas M, Gerfaud-Valentin M, Moulis G, Terriou L, Audia S, Guenin S, Le Guenno G, **Salles G**, Lambotte O, Limal N, Viillard JF, Cheze S, Tomowiak C, Royer B, Neel A, Debouverie O, Hot A, Durieu I, Perlat A, Cliquennois M, Deteix C, Michel M, Godeau B. Characteristics, outcome and response to therapy of multirefractory chronic immune thrombocytopenia. *Blood*. 2016; 128(12):1625-30. <https://www.ncbi.nlm.nih.gov/pubmed/27354722>
265. Chebel A, Catallo R, Mabon C, Bachy E, Wenner T, **Salles G**, Pouteil-Noble C, Ffrench M. Rapamycin safeguards lymphocytes from DNA damage accumulation in vivo *Eur J Cell Biol*. 2016 ;95(9):331-41 <https://www.ncbi.nlm.nih.gov/pubmed/27349711>
266. Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, **Salles G**, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G,

Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2016 Aug;17(8):1081-93. <https://www.ncbi.nlm.nih.gov/pubmed/27345636>

267. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, **Salles G**, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. *Lancet*. 2016 Aug 6;388(10044):565-75. <https://www.ncbi.nlm.nih.gov/pubmed/27313086>
268. Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, Viailly PJ, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, Damotte D, Delarue R, Haioun C, Argueta C, Landesman Y, **Salles G**, Jais JP, Figeac M, Copie-Bergman C, Molina TJ, Picquenot JM, Cornic M, Fest T, Milpied N, Lemasle E, Stamatoullas A, Moeller P, Dyer MJ, Sundstrom C, Bastard C, Tilly H, Leroy K. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. *Am J Hematol*. 2016 ;91(9):923-30. <https://www.ncbi.nlm.nih.gov/pubmed/27312795>
269. Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, **Salles G**, Tilly H. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. *J Clin Oncol*. 2016 Aug 1;34(22):2575-82. <https://www.ncbi.nlm.nih.gov/pubmed/27298402>
270. Manzoni D, Catallo R, Chebel A, Baseggio L, Michallet AS, Roualdes O, Magaud JP, **Salles G**, Ffrench M. The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia. *Leuk Res*. 2016 Aug;47:1-7. <https://www.ncbi.nlm.nih.gov/pubmed/27235717>
271. Meignan M, Cottreau AS, Versari A, Chartier L, Dupuis J, Boussetta S, Grassi I, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, **Salles G**, Luminari S, Trotman J. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. *J Clin Oncol*. 2016 ;34(30):3618-3626 <https://www.ncbi.nlm.nih.gov/pubmed/27551111>
272. Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, Legoff M, Biau D, Anract P, Roux C, Blanc-Autran E, Delarue R, Gisselbrecht C, Ketterer N, Recher C, Bonnet C, Peyrade F, Haioun C, Tilly H, **Salles G**, Brice P, Bouscary D, Deau B, Tamburini J. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. *Leuk Lymphoma*. 2016 Dec;57(12):2820-2826. <https://www.ncbi.nlm.nih.gov/pubmed/27118302>
273. Carras S, Berger F, Chalabreysse L, Callet-Bauchut E, Cordier JF, **Salles G**, Girard N. Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series. *Hematol Oncol*. 2017 Dec;35(4):510-519. <https://www.ncbi.nlm.nih.gov/pubmed/27140394>

274. Traverse-Glehen A, Verney A, Gazzo S, Jallades L, Chabane K, Hayette S, Coiffier B, Callet-Bauchu E, Ffrench M, Felman P, Berger F, Baseggio L, **Salles G**. Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies. *Leuk Lymphoma*. 2017 Mar;58(3):666-675. <https://www.ncbi.nlm.nih.gov/pubmed/27347751>
275. Heiblig M, Elhamri M, Le Jeune C, Laude MC, Deloire A, Wattel E, **Salles G**, Thomas X. Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors. *Eur J Haematol*. 2017 Feb;98(2):134-141. <https://www.ncbi.nlm.nih.gov/pubmed/27717105>
276. Sarkozy C, Molina T, Ghesquières H, Michallet AS, Dupuis J, Damotte D, Morsschauser F, Parrens M, Martin L, Dartigues P, Stamatoullas A, Hirsch P, Fabiani B, Bouabdallah K, da Silva MG, Maerevoet M, Laurent C, Coiffier B, **Salles G**, Traverse-Glehen A. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. *Haematologica*. 2017 Jan;102(1):150-159. <https://www.ncbi.nlm.nih.gov/pubmed/27758822>
277. Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehen A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, **Salles G**, Cerhan JR, Link BK. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. *Am J Hematol*. 2016 Nov;91(11):1096-1101. <https://www.ncbi.nlm.nih.gov/pubmed/27465588>
278. Heiblig M, Le Jeune C, Elhamri M, Balsat M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Nicolini F, Wattel E, **Salles G**, Thomas X. Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience. *Leuk Lymphoma*. 2017 Jan;58(1):110-117. <https://www.ncbi.nlm.nih.gov/pubmed/27184036>
279. Heiblig M, Paubelle E, Plesa A, Geay MO, Manzoni D, Gazzo S, Tigaud I, Callet-Bauchu E, Huet S, **Salles G**, Thomas X, Hayette S, Sujobert P. Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia. *Blood*. 2017 Jan 5;129(1):128-131. <https://www.ncbi.nlm.nih.gov/pubmed/27827828>
280. Sarkozy C, Kaltenbach S, Faurie P, Canioni D, Berger F, Traverse-Glehen A, Ghesquieres H, **Salles G**, Bachy E, Alyanakian MA, Hermine O, Neven B, Macintyre E, Romana S, Molina TJ, Suarez F, Asnafi V, Bruneau J. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders. *Genes Chromosomes Cancer*. 2017 Mar;56(3):221-230. <https://www.ncbi.nlm.nih.gov/pubmed/27750397>
281. Quintela A, Sujobert P, Callet-Bauchu E, **Salles G**, Baseggio L. Ibrutinib-Induced Lymphocytosis: Cytological Features. *Acta Haematol*. 2017;137(1):55-57. <https://www.ncbi.nlm.nih.gov/pubmed/27960168>
282. Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, Maingonnat C, Mareschal S, Picquenot JM, Penther D, Jais JP, Tesson B, Peyrouze P, Figeac M, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Fabiani B, Delarue R, Peyrade F, André M, Ketterer N, Leroy K, **Salles G**, Molina TJ, Tilly H, Jardin F. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. *Clin Cancer Res*. 2017 May 1;23(9):2232-2244. <https://www.ncbi.nlm.nih.gov/pubmed/27923841>
283. Barbaret C, Berthiller J, Schott Pethelaz AM, Michallet M, **Salles G**, Sanchez S, Filbet M. Research protocol on early palliative care in patients with acute leukaemia after one relapse. *BMJ Support Palliat Care*. 2017 Dec;7(4):480-484. <https://www.ncbi.nlm.nih.gov/pubmed/28760818>

284. **Salles G**, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. *Haematologica*. 2017 Apr;102(4):e156-e159. <https://www.ncbi.nlm.nih.gov/pubmed/27979923>
285. Aspeslagh S, Stein M, Bahleda R, Hollebecque A, **Salles G**, Gyan E, Fudio S, Extremera S, Alfaro V, Soto-Matos A, Soria JC. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. *Anticancer Drugs*. 2017 Mar;28(3):341-349. <https://www.ncbi.nlm.nih.gov/pubmed/27977433>
286. Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, **Salles G**, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. *J Clin Oncol*. 2017 Feb 10;35(5):536-543. <https://www.ncbi.nlm.nih.gov/pubmed/27992268>
287. Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, **Salles G**, Sargent DJ. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. *J Clin Oncol*. 2017 Feb 10;35(5):552-560. <https://www.ncbi.nlm.nih.gov/pubmed/28029309>
288. Tixier F, Ranchon F, Iltis A, Vantard N, Schwiertz V, Bachy E, Bouafia-Sauvy F, Sarkozy C, Tournamille JF, Gyan E, **Salles G**, Rioufol C. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. *Hematol Oncol*. 2017; 35(4):584-590 <https://www.ncbi.nlm.nih.gov/pubmed/27377614>
289. Paubelle E, Ducastelle-Leprêtre S, Labussière-Wallet H, Nicolini FE, Barraco F, Plesa A, **Salles G**, Wattel E, Thomas X. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? *Ann Hematol*. 2017 Mar;96(3):363-371. <https://www.ncbi.nlm.nih.gov/pubmed/28011984>
290. Damaj G, Cornillon J, Bouabdallah K, Gressin R, Vigouroux S, Gastinne T, Ranchon F, Ghésquière H, **Salles G**, Yakoub-Agha I, Gyan E. Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. *Bone Marrow Transplant*. 2017 Jul;52(7):941-949. <https://www.ncbi.nlm.nih.gov/pubmed/28112752>
291. Sarkozy C, Huet S, Carlton VE, Fabiani B, Delmer A, Jardin F, Delfau-Larue MH, Hacini M, Ribrag V, Guidez S, Faham M, **Salles G**. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. *Oncotarget*. 2017 Jan 31;8(5):8765-8774. <https://www.ncbi.nlm.nih.gov/pubmed/28060738>
292. Ghesquière H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, **Salles G**. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. *Hematol Oncol*. 2017;35(4):447-455. <https://www.ncbi.nlm.nih.gov/pubmed/27282998>

293. Chien WW, Niogret C, Jugé R, Lionnard L, Cornut-Thibaut A, Kucharczak J, Savina A, **Salles G**, Aouacheria A. Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101. *Leuk Res.* 2017 Apr;55:41-48. <https://www.ncbi.nlm.nih.gov/pubmed/28122282>
294. Huet S, Szafer-Glusman E, Tesson B, Xerri L, Fairbrother WJ, Mukhyala K, Bolen C, Punnoose E, Tonon L, Chassagne-Clément C, Feugier P, Viari A, Jardin F, **Salles G**, Sujobert P. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. *Am J Hematol.* 2017 Jun;92(6):515-519. <https://www.ncbi.nlm.nih.gov/pubmed/28247997>
295. Baudouin A, Fargier E, Cerruti A, Dubromel A, Vantard N, Ranchon F, Schwiertz V, **Salles G**, Souquet PJ, Thomas L, Bérard F, Nancey S, Freyer G, Trillet-Lenoir V, Rioufol C. [Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital]. *Bull Cancer.* 2017 Jun;104(6):538-551. <https://www.ncbi.nlm.nih.gov/pubmed/28237353>
296. Gay C, Delarue R, Milpied N, Oberic L, Coiffier B, Boussetta S, Haioun C, Tilly H, **Salles G**, Lamy T, Lester MA, Houot R. Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area. *Blood.* 2017 May 18;129(20):2811-2813. <https://www.ncbi.nlm.nih.gov/pubmed/28302615>
297. Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, **Salles G**, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. *Blood.* 2017 May 11;129(19):2616-2623. <https://www.ncbi.nlm.nih.gov/pubmed/28251914>
298. Petrella T, Copie-Bergman C, Brière J, Delarue R, Jardin F, Ruminy P, Thieblemont C, Figeac M, Canioni D, Feugier P, Fabiani B, Leroy K, Parrens M, André M, Haioun C, **Salles GA**, Gaulard P, Tilly H, Jais JP, Molina TJ. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. *Ann Oncol.* 2017 May 1;28(5):1042-1049. <https://www.ncbi.nlm.nih.gov/pubmed/28327893>
299. Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, **Salles GA**, Friedberg JW. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. *Blood.* 2017 Jun 1;129(22):3037-3039. <https://www.ncbi.nlm.nih.gov/pubmed/28325864>
300. Vidal L, Gafter-Gvili A, **Salles G**, Bousseta S, Oberman B, Rubin C, van Oers MH, Fortpied C, Ghielmini M, Pettengell R, Witzens-Harig M, Dreger P, Vitolo U, Gomes da Silva M, Evangelista A, Li H, Freedman L, Habermann TM, Shpilberg O. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. *Eur J Cancer.* 2017 May;76:216-225. <https://www.ncbi.nlm.nih.gov/pubmed/28336303>
301. Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, **Salles G**, Dyer MJS. Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. *Blood.* 2017 May 18;129(20):2808-2810. <https://www.ncbi.nlm.nih.gov/pubmed/28377400>
302. Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, **Salles G**, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final Results of the IELSG-19

Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. *J Clin Oncol*. 2017 Jun 10;35(17):1905-1912.
<https://www.ncbi.nlm.nih.gov/pubmed/28355112>

303. Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, **Salles G**, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Clin Cancer Res*. 2017 Aug 1;23(15):4127-4137.
<https://www.ncbi.nlm.nih.gov/pubmed/28381416>
304. Younes A, Hilden P, Coiffier B, Hagenbeek A, **Salles G**, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreundschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). *Ann Oncol*. 2017 Jul 1;28(7):1436-1447.
<https://www.ncbi.nlm.nih.gov/pubmed/28379322>
305. Xerri L, Huet S, Venstrom JM, Szafer-Glusman E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuillères P, Charlotte F, Laurent C, Gelas-Dore B, Bolen CR, Punnoose E, Bouabdallah R, Brice P, Morschhauser F, Cartron G, Olive D, **Salles G**; a LYSA study. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. *Hum Pathol*. 2017 Jun;64:128-136. <https://www.ncbi.nlm.nih.gov/pubmed/28414090>
306. Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E, Hiddemann W, Gaulard P, Xerri L, **Salles G**, Klapper W, Pfreundschuh M, Jack A, Gascoyne RD, Natkunam Y, Advani R, Kimby E, Sander B, Sehn LH, Hagenbeek A, Raemaekers J, Gribben J, Kersten MJ, Ylstra B, Weller E, de Jong D. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. *Haematologica*. 2017 Aug;102(8):1413-1423.
<https://www.ncbi.nlm.nih.gov/pubmed/28411252>
307. Huet S, Xerri L, Tesson B, Mareschal S, Taix S, Mescam-Mancini L, Sohier E, Carrère M, Lazarovici J, Casasnovas O, Tonon L, Boyault S, Hayette S, Haioun C, Fabiani B, Viari A, Jardin F, **Salles G**. EZH2 alterations in follicular lymphoma: biological and clinical correlations. *Blood Cancer J*. 2017 Apr 21;7(4):e555. <https://www.ncbi.nlm.nih.gov/pubmed/28430172>
308. Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, **Salles G**, Gaulard P, Bosly A, Coiffier B. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. *J Clin Oncol*. 2017 Aug 1;35(22):2473-2481.
<https://www.ncbi.nlm.nih.gov/pubmed/28426350>
309. Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T,

- Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, **Salles G**, Molina TJ, Delsol G, Brousset P, Gaulard P. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. *J Clin Oncol*. 2017 Jun 20;35(18):2008-2017. <https://www.ncbi.nlm.nih.gov/pubmed/28459613>
310. Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, **Salles G**, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerd O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte. ABVD or BEACOPP(baseline) along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. *Eur J Cancer*. 2017 Aug;81:45-55. <https://www.ncbi.nlm.nih.gov/pubmed/28601705>
311. Tesson B, Huet S, Grange B, Jallades L, Baseggio L, Felman P, Traverse-Glehen A, Magaud JP, Lega JC, Bole-Feysot C, **Salles G**, Callet-Bauchu E, Sujobert P. Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes. *Blood*. 2017 Sep 7;130(10):1267-1269. <https://www.ncbi.nlm.nih.gov/pubmed/28679739>
312. Jais JP, Molina TJ, Ruminy P, Gentien D, Reyes C, Scott DW, Rimsza LM, Wright G, Gascoyne RD, Staudt LM, Haioun C, Tilly H, Gaulard P, **Salles GA**, Jardin F, Leroy K. Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. *Haematologica*. 2017 Oct;102(10):e404-e406. <https://www.ncbi.nlm.nih.gov/pubmed/28679653>
313. Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado D, Levy N, Bérout C, Felman P, Berger F, Magaud JP, Genestier L, **Salles G**, Traverse-Glehen A. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. *Haematologica*. 2017 Oct;102(10):1758-1766. <https://www.ncbi.nlm.nih.gov/pubmed/28751561>
314. Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, **Salles G**, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. *N Engl J Med*. 2017 Sep 28;377(13):1250-1260. <https://www.ncbi.nlm.nih.gov/pubmed/28953447>
315. Younes A, **Salles G**, Martinelli G, Bociek RG, Barrigon DC, Barca EG, Turgut M, Gerecitano J, Kong O, Pisal CB, Tavorath R, Kim WS. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. *Haematologica*. 2017 Dec;102(12):2104-2112. <https://www.ncbi.nlm.nih.gov/pubmed/28971900>
316. Fargier E, Ranchon F, Huot L, Guerre P, Safar V, Dony A, Hequet N, Bachy E, Savouroux S, Fronteau C, Tomaré P, Tournamille JF, Schwiertz V, Vantard N, Le Gouill S, Gyan E, **Salles G**, Rioufol C. SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. *Ann Hematol*. 2018 Jan;97(1):123-131. <https://www.ncbi.nlm.nih.gov/pubmed/28993857>

317. Ranchon F, Vantard N, Henin E, Bachy E, Sarkozy C, Karlin L, Bouafia-Sauvy F, Gouraud A, Schwiertz V, Bourbon E, Baudouin A, Caffin AG, Vial T, **Salles G**, Rioufol C. Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences? *Hematol Oncol.* 2018;36(2):399-406 <https://www.ncbi.nlm.nih.gov/pubmed/28983943>
318. Bobée V, Ruminy P, Marchand V, Viailly PJ, Abdel Sater A, Veresezan L, Drieux F, Bérard C, Bohers E, Mareschal S, Dubois S, Jais JP, Leroy K, Figeac M, Picquenot JM, Molina TJ, **Salles G**, Haioun C, Tilly H, Jardin F. Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study. *J Mol Diagn.* 2017 Nov;19(6):892-904. <https://www.ncbi.nlm.nih.gov/pubmed/29054399>
319. Hirz T, Matera EL, Chettab K, Jordheim LP, Mathé D, Evesque A, Esmenjaud J, **Salles G**, Dumontet C. Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding. *Oncotarget.* 2017 Aug 18;8(42):72818-72834. <https://www.ncbi.nlm.nih.gov/pubmed/29069828>
320. Rossi C, Mounier M, Brice P, Safar V, Nicolas-Virelizier E, Rey P, Stamatoullas-Bastard A, Alcantara M, Chauchet A, Reboursière E, Filliatre L, Perrot A, Garcia S, **Salles G**, Coiffier B, Ghesquières H, Casasnovas RO. Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. *Oncotarget.* 2017 19;8(49):85110-85119. <https://www.ncbi.nlm.nih.gov/pubmed/29156707>
321. Bernatsky S, Velásquez García HA, Spinelli JJ, Gaffney P, Smedby KE, Ramsey-Goldman R, Wang SS, Adami HO, Albanes D, Angelucci E, Ansell SM, Asmann YW, Becker N, Benavente Y, Berndt SI, Bertrand KA, Birmann BM, Boeing H, Boffetta P, Bracci PM, Brennan P, Brooks-Wilson AR, Cerhan JR, Chanock SJ, Clavel J, Conde L, Cotenbader KH, Cox DG, Cozen W, Crouch S, De Roos AJ, de Sanjose S, Di Lollo S, Diver WR, Dogan A, Foretova L, Ghesquières H, Giles GG, Glimelius B, Habermann TM, Haioun C, Hartge P, Hjalgrim H, Holford TR, Holly EA, Jackson RD, Kaaks R, Kane E, Kelly RS, Klein RJ, Kraft P, Krickler A, Lan Q, Lawrence C, Liebow M, Lightfoot T, Link BK, Maynadie M, McKay J, Melbye M, Molina TJ, Monnereau A, Morton LM, Nieters A, North KE, Novak AJ, Offit K, Purdue MP, Rais M, Riby J, Roman E, Rothman N, **Salles G**, Severi G, Severson RK, Skibola CF, Slager SL, Smith A, Smith MT, Southey MC, Staines A, Teras LR, Thompson CA, Tilly H, Tinker LF, Tjonneland A, Turner J, Vajdic CM, Vermeulen RCH, Vijai J, Vineis P, Virtamo J, Wang Z, Weinstein S, Witzig TE, Zelenetz A, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Zucca M, Clarke AE. Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. *Lupus Sci Med.* 2017 Nov 12;4(1):e000187. <https://www.ncbi.nlm.nih.gov/pubmed/29214033>
322. Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, Gomes da Silva M, Bouabdallah R, **Salles G**, Bachy E. Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers. *Ann Oncol.* 2018 Mar 1;29(3):715-723 <https://www.ncbi.nlm.nih.gov/pubmed/29253087>
323. Bolen CR, McCord R, Huet S, Frampton GM, Bourgon R, Jardin F, Dartigues P, Punnoose EA, Szafer-Glusman E, Xerri L, Sujobert P, **Salles G**, Venstrom JM. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. *Blood Adv.* 2017 Sep 27;1(22):1884-1890. <https://www.ncbi.nlm.nih.gov/pubmed/29296835>

324. Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, Tigaud I, Pages MP, Chelghoum Y, Baracco F, Labussierre H, Ducastelle S, Paubelle E, Nicolini FE, Elhamri M, Campos L, Plesa C, Morisset S, **Salles G**, Bertrand Y, Michallet M, Thomas X. High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. *World J Stem Cells*. 2017 Dec 26;9(12):227-234. <https://www.ncbi.nlm.nih.gov/pubmed/29321824>
325. Ghesquières H, Larrabee BR, Casasnovas O, Maurer MJ, McKay JD, Ansell SM, Montgomery D, Asmann YW, Farrell K, Verney A, Slager SL, Allmer C, Perrot A, Delarue R, Habermann TM, Dupuis J, Link BK, Canioni D, Dogan A, Cozen W, Jarrett RF, Cerhan JR, **Salles G**. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. *Br J Haematol*. 2018 Jan;180(2):286-290. <https://www.ncbi.nlm.nih.gov/pubmed/27716907>
326. Guillermin Y, Herbaux C, Subtil F, Aurrant-Schleinitz T, Cymbalista F, Letestu R, Leprêtre S, Vaudaux S, Laribi K, Leblond V, Defoi Y, Benchikh R, **Salles G**, Godmer P, Jardel H, Vallais F, Feugier P, Orsini F, Pegourié B, Lévy V, Michallet AS. Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group. *Am J Hematol*. 2018 Jan;93(1):E24-E27. <https://www.ncbi.nlm.nih.gov/pubmed/29055105>
327. Avivi I, Boumendil A, Finel H, Nagler A, de Sousa AB, Santasusana JMR, Vandenberghe E, Afanasyev B, Bordessoule D, Moraleda JM, Garcia EC, Pohlreich D, Garcia GG, Thomson K, Or R, Beelen D, Zuffa E, Giebel S, Berthou C, **Salles G**, Melpignano A, Montoto S, Dreger P. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2018 ;53(8):1001-1009. <https://www.ncbi.nlm.nih.gov/pubmed/29463854>
328. Collins GP, Rueda A, **Salles G**, von Tresckow B, Zaja F. Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. *Leuk Lymphoma*. 2018 Jan 16:1-8. <https://www.ncbi.nlm.nih.gov/pubmed/29334819>
329. Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, **Salles G**. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. *Lancet Oncol*. 2018;19(4):549-561. <https://www.ncbi.nlm.nih.gov/pubmed/29475724>
330. Feugier P, Brice P, Maynadié M, Franchi-Rezgui P, Hacini M, Laurent G, Suc E, Fitoussi O, Solal-Celigny P, Damaj G, Haioun C, Leconte P, Lazreg F, Boissard F, Pau D, **Salles G**. Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study. *Leuk Lymphoma*. 2018 Feb 28:1-4. <https://www.ncbi.nlm.nih.gov/pubmed/29486625>
331. Cottreau AS, Versari A, Luminari S, Dupuis J, Chartier L, Casasnovas RO, Berriolo-Riedinger A, Menga M, Haioun C, Tilly H, Tarantino V, Federico M, **Salles G**, Trotman J, Meignan M. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. *Blood*. 2018 May 31;131(22):2449-2453. <https://www.ncbi.nlm.nih.gov/pubmed/29559480>

332. Perry M, Bertoli S, Rocher C, Hayette S, Ducastelle S, Barraco F, Labussière-Wallet H, **Salles G**, Recher C, Thomas X, Paubelle E. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2018 Jun 13. pii: S2152-2650(18)30224-6. <https://www.ncbi.nlm.nih.gov/pubmed/30082225>
333. Verney A, Traverse-Glehen A, Callet-Bauchu E, Jallades L, Magaud JP, **Salles G**, Genestier L, Baseggio L. Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma. *Oncotarget*. 2018 May 4;9(34):23589-23598. <https://www.ncbi.nlm.nih.gov/pubmed/29805758>
334. Wang SS, Carrington M, Berndt SI, Slager SL, Bracci PM, Voutsinas J, Cerhan JR, Smedby KE, Hjalgrim H, Vijai J, Morton LM, Vermeulen R, Paltiel O, Vajdic CM, Linet MS, Nieters A, de Sanjose S, Cozen W, Brown EE, Turner J, Spinelli JJ, Zheng T, Birmann BM, Flowers CR, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Albanes D, Weinstein SJ, Teras LR, Diver WR, Lax SJ, Travis RC, Kaaks R, Riboli E, Benavente Y, Brennan P, McKay J, Delfau-Larue MH, Link BK, Magnani C, Ennas MG, Latte G, Feldman AL, Doo NW, Giles GG, Southey MC, Milne RL, Offit K, Musinsky J, Arslan AA, Purdue MP, Adami HO, Melbye M, Glimelius B, Conde L, Camp NJ, Glenn M, Curtin K, Clavel J, Monnereau A, Cox DG, Ghesquières H, **Salles G**, Bofetta P, Foretova L, Staines A, Davis S, Severson RK, Lan Q, Brooks-Wilson A, Smith MT, Roman E, Krickler A, Zhang Y, Kraft P, Chanock SJ, Rothman N, Hartge P, Skibola CF. HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. *Cancer Res*. 2018 Jul 15;78(14):4086-4096. <https://www.ncbi.nlm.nih.gov/pubmed/29735552>
335. Filliatre-Clement L, Maucort-Boulch D, Bourbon E, Karlin L, Safar V, Bachy E, Sesques P, Ferrant E, Bouafia F, Lazareth A, Ghergus D, Coiffier B, Traverse Glehen A, **Salles G**, Ghesquieres H, Sarkozy C. Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes. *Hematol Oncol*. 2018 May 2. <https://www.ncbi.nlm.nih.gov/pubmed/29722049>
336. Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, Marie D, André P, Paturel C, Zerbib R, Bennouna J, **Salles G**, Gonçalves A. A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. *Oncotarget*. 2018 Apr 3;9(25):17675-17688. <https://www.ncbi.nlm.nih.gov/pubmed/29707140>
337. Besson L, Charrier E, Karlin L, Allatif O, Marçais A, Rouzair P, Belmont L, Attal M, Lombard C, **Salles G**, Walzer T, Viel S. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy. *Front Immunol*. 2018 Apr 13;9:704. <https://www.ncbi.nlm.nih.gov/pubmed/29706958>
338. Collinge E, Loron S, Larcher MV, Elhamri M, Heiblig M, Deloire A, Ducastelle S, Labussière H, Barraco F, Wattel E, **Salles G**, Paubelle E, Thomas X. Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease. *Clin Lymphoma Myeloma Leuk*. 2018 May;18(5):e211-e218. <https://www.ncbi.nlm.nih.gov/pubmed/29572159>
339. Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, **Salles GA**, Witzig TE, Tilly H, Nowakowski GS. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has

Implication for Bias in Clinical Trials. *J Clin Oncol*. 2018 Jun 1;36(16):1603-1610.
<https://www.ncbi.nlm.nih.gov/pubmed/29672223>

340. Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucourt-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, **Salles G**. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. *Blood*. 2018 Jul 5;132(1):49-58.
<https://www.ncbi.nlm.nih.gov/pubmed/29666118>
341. Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Álvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T, Blaker YN, **Salles G**, Coiffier B; Aristotle Consortium. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. *Lancet Haematol*. 2018 Aug;5(8):e359-e367.
<https://www.ncbi.nlm.nih.gov/pubmed/30078408>
342. Morschhauser F, **Salles G**, Le Gouill S, Tilly H, Thieblemont C, Bouabdallah K, Fabiani B, Ménard C, Tarte K, Cartron G, Houot R. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. *Blood*. 2018 Oct 4;132(14):1486-1494. <https://www.ncbi.nlm.nih.gov/pubmed/30068505>
343. Huet S, Paubelle E, Lours C, Grange B, Courtois L, Chabane K, Charlot C, Mosnier I, Simonet T, Hayette S, Tigaud I, Thomas X, **Salles G**, Subtil F, Sujobert P. Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life. *Blood*. 2018 Aug 23;132(8):865-867. <https://www.ncbi.nlm.nih.gov/pubmed/29866812>
344. Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, **Salles G**. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. *J Clin Oncol*. 2018 Aug 10;36(23):2405-2412.
<https://www.ncbi.nlm.nih.gov/pubmed/29851546>
345. Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, **Salles G**, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. *J Clin Oncol*. 2018 Aug 1;36(22):2259-2266.
<https://www.ncbi.nlm.nih.gov/pubmed/29584548>
346. Milpied P, Cervera-Marzal I, Mollichella ML, Tesson B, Brisou G, Traverse-Glehen A, **Salles G**, Spinelli L, Nadel B. Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. *Nat Immunol*. 2018 Sep;19(9):1013-1024.
<https://www.ncbi.nlm.nih.gov/pubmed/30104629>
347. Favre R, Manzoni D, Traverse-Glehen A, Verney A, Jallades L, Callet-Bauchu E, Sujobert P, **Salles G**, Baseggio L. Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL. *Int J Lab Hematol*. 2018 Aug;40(4):e59-e62. <https://www.ncbi.nlm.nih.gov/pubmed/29659173>
348. Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, **Salles G**; Lymphoma Study Association. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase

- 2 study. *Lancet Haematol.* 2018 Sep;5(9):e403-e410.
<https://www.ncbi.nlm.nih.gov/pubmed/30172345>
349. Balsat M, Etienne M, Elhamri M, Hayette S, **Salles G**, Thomas X. Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era. *Eur J Haematol.* 2018 ;101(6):774-780
<https://www.ncbi.nlm.nih.gov/pubmed/30179268>
350. Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, **Salles GA**; RELEVANCE Trial Investigators. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. *N Engl J Med.* 2018 Sep 6;379(10):934-947.
<https://www.ncbi.nlm.nih.gov/pubmed/30184451>
351. Robinot R, Bachy E, Chaubard S, Urb M, Carras S, Bardel E, Chartoire D, Traverse-Glehen A, Marche PN, **Salles G**, Jaulhac B, Genestier L. Chronic *Borrelia burgdorferi* infection triggers NKT lymphomagenesis. *Blood.* 2018 Dec 20;132(25):2691-2695.
<https://www.ncbi.nlm.nih.gov/pubmed/30389696>
352. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, **Salles G***, Maziarz RT*; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med.* 2019 Jan 3;380(1):45-56. (* *co-senior authors*)
<https://www.ncbi.nlm.nih.gov/pubmed/30501490>
353. Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, Traverse-Glehen A, Feldman AL, Allmer C, Slager SL, Ansell SM, Habermann TM, Bachy E, Cerhan JR, **Salles G**. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. *J Clin Oncol.* 2019 Jan 10;37(2):144-152.
<https://www.ncbi.nlm.nih.gov/pubmed/30481079>
354. **Salles G**, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schechter JM, Wang M. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. *Clin Lymphoma Myeloma Leuk.* 2019 Jan 2. pii: S2152-2650(18)31284-9. <https://www.ncbi.nlm.nih.gov/pubmed/30795996>
355. Conrad A, Boccard M, Valour F, Alcazer V, Tovar Sanchez AT, Chidiac C, Laurent F, Vanhems P, **Salles G**, Brengel-Pesce K, Meunier B, Trouillet-Assant S, Ader F; Lyon HEMINF Study Group. VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients. *BMJ Open.* 2019 Feb 15;9(2):e026093. <https://www.ncbi.nlm.nih.gov/pubmed/30772864>
356. Alcazer V, Conrad A, Valour F, Bachy E, **Salles G**, Huynh A, de Latour RP, Labussière-Wallet H, Ader F. Early-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure. *Am J Hematol.* 2019 Apr;94(4):E109-E111.
<https://www.ncbi.nlm.nih.gov/pubmed/30663089>
357. Sarkozy C, Copie-Bergman C, Damotte D, Ben-Neriah S, Burroni B, Cornillon J, Lemal R, Golfier C, Fabiani B, Chassagne-Clément C, Parrens M, Herbaux C, Xerri L, Bossard C, Laurent C, Cheminant M, Cartron G, Cabecadas J, Molina T, **Salles G**, Steidl C, Ghesquière H, Mottok A, Traverse-Glehen A. Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A

Histopathologic Series From the LYSA. *Am J Surg Pathol*. 2019 Mar;43(3):341-351.
<https://www.ncbi.nlm.nih.gov/pubmed/30540571>

358. Heiblig M, Sujobert P, Hayette S, Balsat M, Elhamri M, **Salles G**, Thomas X. Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience. *Leuk Res*. 2019 Jan;76:29-32. <https://www.ncbi.nlm.nih.gov/pubmed/30529680>
359. Bal A, Sarkozy C, Josset L, Cheynet V, Oriol G, Becker J, Vilchez G, Sesques P, Mallet F, Pachot A, Morfin F, Lina B, **Salles G**, Reynier F, Trouillet-Assant S, Brengel-Pesce K. Metagenomic Next-Generation Sequencing Reveals Individual Composition and Dynamics of Anelloviruses during Autologous Stem Cell Transplant Recipient Management. *Viruses*. 2018 Nov 14;10(11). <https://www.ncbi.nlm.nih.gov/pubmed/30441786>
360. Houot R, Cartron G, Bijou F, de Guibert S, **Salles GA**, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, Van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. *Leukemia*. 2019 Mar;33(3):776-780. <https://www.ncbi.nlm.nih.gov/pubmed/30291335>
361. Zelenetz AD, **Salles G**, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Cartron G, Chamuleau MED, Goy A, Tam CS, Lugtenburg PJ, Petrich AM, Sinha A, Samineni D, Herter S, Ingalla E, Szafer-Glusman E, Klein C, Sampath D, Kornacker M, Mobasher M, Morschhauser F. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. *Blood*. 2019 ;133(18):1964-1976 <https://www.ncbi.nlm.nih.gov/pubmed/30850381>
362. Heiblig M, Labussière-Wallet H, Nicolini FE, Michallet M, Hayette S, Sujobert P, Plesa A, Balsat M, Paubelle E, Barraco F, Tigaud I, Ducastelle S, Wattel E, **Salles G**, Thomas X. Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience. *Cancers (Basel)*. 2019 Apr 22;11(4). <https://www.ncbi.nlm.nih.gov/pubmed/31013658>
363. Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, **Salles G**, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). *Lancet Haematol*. 2019 May;6(5):e254-e265. <https://www.ncbi.nlm.nih.gov/pubmed/30935953>
364. Benech N, Dumitrescu O, Conrad A, Balsat M, Paubelle E, Ducastelle-Lepretre S, Labussière-Wallet H, **Salles G**, Cohen S, Goutelle S, Ader F; Lyon HEMINF Study Group . Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study. *J Antimicrob Chemother*. 2019; 74(9):2676-2680 <https://www.ncbi.nlm.nih.gov/pubmed/31219562>
365. Cornillon J, Daguene E, Bay JO, Chauchet A, **Salles G**, Contentin N, Nicolas-Virelizier E, Mercier M, Vallet N, Alexis M, Chrétien ML, Cluzeau T, Huynh A, Hemberlin C, Dorvaux V, Amorim S, Lejeune C, de Latour RP, Gyan E. BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). *Ann Hematol*. 2019 ;98(8):1973-1980. <https://www.ncbi.nlm.nih.gov/pubmed/31111177>
366. Balsat M, Pillet S, Tavernier E, Cacheux V, Escuret V, Moluçon-Chabrot C, Augeul-Meunier K, Mirand A, Regagnon C, Tinquaut F, Bousser V, Oriol M, Guyotat D, **Salles G**, Bay JO, Pozzetto B, Cornillon J. Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter

prospective study in adult patients. *J Infect.* 2019 ;79(1):36-42.
<https://www.ncbi.nlm.nih.gov/pubmed/31075291>

367. Mounier N, Anthony S, Busson R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais-Guillaumot F, Damaj G, Nerich V, Jais JP, Laborde L, **Salles G**, Henry-Amar M. Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. *Cancer.* 2019 Mar 22. doi: 10.1002/cncr.32040. [Epub ahead of print]
<https://www.ncbi.nlm.nih.gov/pubmed/30901086>
368. Tilly H, Morschhauser F, Bartlett NL, Mehta A, **Salles G**, Haioun C, Munoz J, Chen AI, Kolibaba K, Lu D, Yan M, Penuel E, Hirata J, Lee C, Sharman JP. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. *Lancet Oncol.* 2019 ;20(7):998-1010
<https://www.ncbi.nlm.nih.gov/pubmed/31101489>
369. Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, **Salles GA**, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, Houot R. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. *Lancet Haematol.* 2019 ;6(8):e429-e437. <https://www.ncbi.nlm.nih.gov/pubmed/31296423>
370. Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, **Salles G**, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, de Guibert S, Orsini F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan Graczyk M, Vilque JP, Aurrant T, Cymbalista F, Lepretre S, Lévy V, Nguyen-Khac F, Le Garff-Tavernier M, Aanei C, Ticchioni M, Letestu R, Feugier P. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. *Lancet Haematol.* 2019 ;6(9):e470-e479.
<https://www.ncbi.nlm.nih.gov/pubmed/31324600>
371. Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, **Salles G**. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. *J Clin Oncol.* 2019 ;37(31):2815-2824.
<https://www.ncbi.nlm.nih.gov/pubmed/31339826>
372. Din L, Sheikh M, Kosaraju N, Smedby KE, Bernatsky S, Berndt SI, Skibola CF, Nieters A, Wang S, McKay JD, Cocco P, Maynadié M, Foretová L, Staines A, Mack TM, de Sanjosé S, Vyse TJ, Padyukov L, Monnereau A, Arslan AA, Moore A, Brooks-Wilson AR, Novak AJ, Glimelius B, Birmann BM, Link BK, Stewart C, Vajdic CM, Haioun C, Magnani C, Conti DV, Cox DG, Casabonne D, Albanes D, Kane E, Roman E, Muzi G, **Salles G**, Giles GG, Adami HO, Ghesquières H, De Vivo I, Clavel J, Cerhan JR, Spinelli JJ, Hofmann J, Vijai J, Curtin K, Costenbader KH, Onel K, Offit K, Teras LR, Morton L, Conde L, Miligi L, Melbye M, Ennas MG, Liebow M, Purdue MP, Glenn M, Southey MC, Din M, Rothman N, Camp NJ, Wong Doo N, Becker N, Pradhan N, Bracci PM, Boffetta P, Vineis P, Brennan P, Kraft P, Lan Q, Severson RK, Vermeulen RCH, Milne RL, Kaaks R, Travis RC, Weinstein SJ, Chanock SJ, Ansell SM, Slager SL, Zheng T, Zhang Y, Benavente Y, Taub Z, Madireddy L, Gourraud PA, Oksenberg JR, Cozen W, Hjalgrim H, Khankhanian P. Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. *Genet Epidemiol.* 2019 ;43(7):844-863. <https://www.ncbi.nlm.nih.gov/pubmed/31407831>

373. Dony A, Belhabri A, Bertrand Y, Sebban C, Cony-Makhoul P, Sobh M, Rogasik M, **Salles G**, Anglaret B, Freycon C, Corm S, Faurie P, Cornillon J, Michallet AS, Chassagne-Clément C, Berger F, Ray-Coquard IL. Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region. *J Adolesc Young Adult Oncol*. 2019 ;8(6):684-696. <https://www.ncbi.nlm.nih.gov/pubmed/31411521>
374. Deshayes S, Khellaf M, Zarour A, Layese R, Fain O, Terriou L, Viillard JF, Cheze S, Graveleau J, Slama B, Audia S, Cliquennois M, Ebbo M, Le Guenno G, **Salles G**, Bonmati C, Teillet F, Galicier L, Lambotte O, Hot A, Lefrère F, Mahévas M, Canoui-Poitrine F, Michel M, Godeau B. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. *Am J Hematol*. 2019 94(12):1314-1324. <https://www.ncbi.nlm.nih.gov/pubmed/31489694>
375. Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, **Salles G**, Burton C, de Jong D, Sehn LH, Maucort-Boulch D. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. *J Clin Oncol*. 2019 Dec 10;37(35):3359-3368. <https://www.ncbi.nlm.nih.gov/pubmed/31498031>
376. Degaud M, Baseggio L, Grange B, Manzoni D, Huet S, Callet-Bauchu E, Traverse-Glehen A, Davi F, Ghesquières H, **Salles G**, Sujobert P. Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort. *Cancers (Basel)*. 2019 Oct 4;11(10). <https://www.ncbi.nlm.nih.gov/pubmed/31590326>
377. Bal A, Oriol G, Josset L, Genereuz L, Sarkozy C, Sesques P, **Salles G**, Morfin F, Lina B, Becker J, Reynier F, Mallet F, Pachot A, Cheynet V, Brengel-Pesce K, Trouillet-Assant S. Metagenomic Investigation of Torque Teno Mini Virus-SH in Hematological Patients. *Front Microbiol*. 2019 ;10:1898. <https://www.ncbi.nlm.nih.gov/pubmed/31620095>
378. Dubois S, Tesson B, Mareschal S, Viailly PJ, Bohers E, Ruminy P, Etancelin P, Peyrouze P, Copie-Bergman C, Fabiani B, Petrella T, Jais JP, Haioun C, **Salles G**, Molina TJ, Leroy K, Tilly H, Jardin F; Lymphoma Study Association (LYSA) investigators. Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles. *EBioMedicine*. 2019 ;48:58-69. <https://www.ncbi.nlm.nih.gov/pubmed/31648986>
379. Morschhauser F, Machiels JP, **Salles G**, Rottey S, Rule SA, Cunningham D, Peyrade F, Fruchart C, Arkenau HT, Genvresse I, Liu L, Köchert K, Shen K, Kneip C, Peña CE, Grevel J, Zhang J, Cisternas G, Reschke S, Granvil C, Awada A. On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors. *Mol Cancer Ther*. 2019 Oct 16. <https://www.ncbi.nlm.nih.gov/pubmed/31619463>
380. **Salles G**, Bachy E, Smolej L, Simkovic M, Baseggio L, Panovska A, Besson H, Healy N, Garside J, Iraqi W, Diels J, Pick-Lauer C, Spacek M, Urbanova R, Lysak D, Hermans R, Lundbom J, Callet-Bauchu E, Doubek M. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. *Ann Hematol*. 2019n;98(12):2749-2760. <https://www.ncbi.nlm.nih.gov/pubmed/31745601>

381. Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, **Salles G**, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orłowski R, Shipp M, Zinzani PL. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. *J Clin Oncol*. 2019 Dec 1;37(34):3291-3299.
382. Paubelle E, Plesa A, Hayette S, Elhamri M, Zylbersztejn F, Hermine O, **Salles G**, Thomas X. Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1. *Oncol Ther*. 2019 Dec;7(2):121-130. doi: 10.1007/s40487-019-0095-9. Epub 2019 May 22. PMID: 32699982; PMCID: PMC7359977.
383. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, **Salles G**, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. *J Clin Oncol*. 2020 Jan 20;38(3):248-256. <https://www.ncbi.nlm.nih.gov/pubmed/31804876>
384. Rule SA, Cartron G, Fegan C, Morschhauser F, Han L, Mitra S, **Salles G**, Dyer MJS. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). *Leukemia*. 2019 Dec 11. [Epub ahead of print] <https://www.ncbi.nlm.nih.gov/pubmed/31827243>
385. Kleinstern G, Yan H, Hildebrandt MAT, Vijai J, Berndt SI, Ghesquières H, McKay J, Wang SS, Nieters A, Ye Y, Monnereau A, Brooks-Wilson AR, Lan Q, Melbye M, Jackson RD, Teras LR, Purdue MP, Vajdic CM, Vermeulen RCH, Giles GG, Cocco PL, Birmann BM, Kraft P, Albanes D, Zeleniuch-Jacquotte A, Crouch S, Zhang Y, Sarangi V, Asmann Y, Offit K, **Salles G**, Wu X, Smedby KE, Skibola CF, Slager SL, Rothman N, Chanock SJ, Cerhan JR. Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. *Hum Mol Genet*. 2019 Oct 10. <https://www.ncbi.nlm.nih.gov/pubmed/31600786>
386. Pettengell R, Długosz-Danecka M, Andorsky D, Belada D, Georgiev P, Quick D, Singer JW, Singh SB, Pallis A, Egorov A, **Salles G**. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). *Br J Haematol*. 2020;188(2):240-248. <https://www.ncbi.nlm.nih.gov/pubmed/3187994>
387. Sesques P, Bourcier J, Golfier C, Lebras L, Nicolas-Virelizier E, Hacini M, Perrin MC, Voillat L, Bachy E, Traverse-Glehen A, Moreau A, Martin L, Ramla S, Casasnovas O, Le Gouill S, **Salles G**, Ghesquières H. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. *Hematol Oncol*. 2020 Jan 18. doi: [Epub ahead of print] <https://www.ncbi.nlm.nih.gov/pubmed/31953963>
388. Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, **Salles GA**, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin Garcia-Sancho A, Verhoef G, Van Den Neste EW, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, Wei X, Hege KM, Trotter MWB, Risueno A, Buchholz T, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier. *Blood*. 2020 Jan 23. [Epub ahead of print] <https://www.ncbi.nlm.nih.gov/pubmed/31977002>
389. Vercellino L, Cottreau AS, Casasnovas RO, Tilly H, Feugier P, Chartier L, Fruchart C, Roulin L, Obéric L, Pica GM, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O,

- Sebban CJ, López-Guillermo A, Sanhes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Briere J, **Salles GA**, Gaulard P, Meignan M, Thieblemont C. High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP. *Blood*. 2020 Apr 16;135(16):1396-1405. doi: 10.1182/blood.2019003526. PMID: 31978225
390. Huet S, Bouvard A, Ferrant E, Mosnier I, Chabane K, **Salles G**, Michallet AS, Hayette S, Sjobert P. Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia. *Leukemia*. 2020 Jan 29. [Epub ahead of print] <https://www.ncbi.nlm.nih.gov/pubmed/31996767>
391. Lenz G, Hawkes E, Verhoef G, Haioun C, Lim ST, Heo DS, Ardeschna K, Chong G, Haaber J, Shi W, Gorbachevsky I, Lippert S, Hiemeyer F, Piraino P, Beckmann G, Peña C, Buvaylo V, Childs BH, and **Salles G**. Phase II Trial of Single-Agent Copanlisib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Leukemia*. 2020 Feb 14. doi: 10.1038/s41375-020-0743-y. Epub ahead of print. PMID: 32060403.
392. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, **Salles G**, Wierda WG, Izumi, Munugalavadla V, Patel, Wang MH, Wong S, and Byrd JC. Acalabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukaemia: The Randomised, Controlled, Phase 3 ELEVATE TN Trial. *Lancet*. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. Erratum in: *Lancet*. 2020 May *Lancet*
393. Relecom A, Federico M, Connors JM, Coiffier B, Biasoli I, Moccia A, **Salles G**, McKee T, Miralbell R, Borchmann P, Kuruvilla J, Johnson P, Cavalli F, Delavy M, Dietrich PY, Flahault A. Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. *Int J Environ Res Public Health*. 2020 Mar 9;17(5):1783. doi: 10.3390/ijerph17051783. PMID: 32182952; PMCID: PMC7084688.
394. Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, **Salles G**, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. *Invest New Drugs*. 2020 Mar 14. doi: 10.1007/s10637-020-00916-3. Epub ahead of print. Erratum in: *Invest New Drugs*. 2020 May 31;: Erratum in: *Invest New Drugs*. 2020 Jun 23;: PMID: 32172489.
395. Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, **Salles GA**, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv*. 2020 Feb 25;4(4):629-637. doi: 10.1182/bloodadvances.2019001026. PMID: 32074277; PMCID: PMC7042998.
396. Moore A, Kane E, Wang Z, Panagiotou OA, Teras LR, Monnereau A, Wong Doo N, Machiela MJ, Skibola CF, Slager SL, **Salles G**, Camp NJ, Bracci PM, Nieters A, Vermeulen RCH, Vijai J, Smedby KE, Zhang Y, Vajdic CM, Cozen W, Spinelli JJ, Hjalgrim H, Giles GG, Link BK, Clavel J, Arslan AA, Purdue MP, Tinker LF, Albanes D, Ferri GM, Habermann TM, Adami HO, Becker N, Benavente Y, Bisanzi S, Boffetta P, Brennan P, Brooks-Wilson AR, Canzian F, Conde L, Cox DG, Curtin K, Foretova L, Gapstur SM, Ghesquières H, Glenn M, Glimelius B, Jackson RD, Lan Q, Liebow M, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Morton LM, North KE, Offit K, Padoan M, Patel AV, Piro S, Ravichandran V, Riboli E, de Sanjose S, Severson RK, Southey MC, Staines A, Stewart C, Travis RC, Weiderpass E, Weinstein S, Zheng T, Chanock SJ, Chatterjee N, Rothman N, Birmann BM, Cerhan JR, Berndt SI. Genetically Determined Height and

- Risk of Non-hodgkin Lymphoma. *Front Oncol.* 2020 Jan 28;9:1539. doi: 10.3389/fonc.2019.01539. PMID: 32064237; PMCID: PMC6999122.
397. Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, **Salles G**, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. *Am J Hematol.* 2020 May;95(5):510-520. doi: 10.1002/ajh.25757. Epub 2020 Feb 29. PMID: 32052473.
398. Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, **Salles G**, Maziarz RT, Anak Ö, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. *Blood Adv.* 2020 Feb 11;4(3):560-572. doi: 10.1182/bloodadvances.2019000525. PMID: 32045475; PMCID: PMC7013261.
399. Aussedat G, Traverse-Glehen A, Stamatoullas A, Molina T, Safar V, Laurent C, Michot JM, Hirsch P, Nicolas-Virelizier E, Lamure S, Regny C, Picquenot JM, Ledoux-Pilon A, Tas P, Chassagne-Clément C, Manson G, Lemal R, Fontaine J, Le Cann M, **Salles G**, Ghesquières H, Copie-Bergman C, Sarkozy C. Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. *Br J Haematol.* 2020 Apr;189(2):244-256. doi: 0.1111/bjh.16331. Epub 2020 Feb 6. PMID: 32030731.
400. Wallet F, Bachy E, Vassal O, Friggeri A, Bohe J, Garnier L, **Salles G**, Allaouchiche B. Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS). *Bone Marrow Transplant.* 2020 Apr 10. doi: 10.1038/s41409-020-0896-3. Epub ahead of print. PMID: 32277144.
401. Libre C, Moro-Sibilot L, Giraud S, Martin L, Verhoeyen E, Costa C, Chebel A, Bissay N, **Salles G**, Genestier L, Sujobert P. Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant. *Cancers (Basel).* 2020 Apr 7;12(4):901. doi: 10.3390/cancers12040901. PMID: 32272741; PMCID: PMC7226254.
402. Ruppert AS, Dixon JG, **Salles G**, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquières H, Ziepert M, Flament J, Flowers C, Shi Q, Schmitz N. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. *Blood.* 2020 Jun 4;135(23):2041-2048. doi: 10.1182/blood.2019002729. PMID: 32232482.
403. Herledan C, Ranchon F, Schwiertz V, Baudouin A, Karlin L, Ghesquières H, **Salles G**, Rioufol C. Drug cost savings in phase III hematological oncology clinical trials in a university hospital. *Hematol Oncol.* 2020 May 29. doi: 10.1002/hon.2753. Epub ahead of print. PMID: 32469095.
404. Bobée V, Drieux F, Marchand V, Sater V, Veresezan L, Picquenot JM, Viailly PJ, Lanic MD, Viennot M, Bohers E, Oberic L, Copie-Bergman C, Molina TJ, Gaulard P, Haioun C, **Salles G**, Tilly H, Jardin F, Ruminy P. Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma. *Blood Cancer J.* 2020 May 22;10(5):59. doi: 10.1038/s41408-020-0322-5. PMID: 32444689; PMCID: PMC7244768.
405. Conrad A, Perry M, Langlois ME, Labussière-Wallet H, Barraco F, Ducastelle-Leprêtre S, Larcher MV, Balsat M, Boccard M, Chidiac C, Ferry T, Roure-Sobas C, **Salles G**, Valour F, Ader F; Lyon HemInf Study Group. Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2020 May 17:S1083-8791(20)30294-9. doi: 10.1016/j.bbmt.2020.05.006. Epub ahead of print. PMID: 32428736.
406. Laurino M, Loron S, Larcher MV, Fossard G, Elhamri M, Deloire A, Balsat M, Barraco F, Labussière H, Ducastelle S, Renault M, Wattel E, Heiblig M, **Salles G**, Thomas X. Lyon-University

- Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study. *Mediterr J Hematol Infect Dis*. 2020 May 1;12(1):e2020020. doi: 10.4084/MJHID.2020.020. PMID: 32395209; PMCID: PMC7202336.
407. Sarkozy C, Chong L, Takata K, Chavez EA, Miyata-Takata T, Duns G, Telenius A, Boyle M, Slack GW, Laurent C, Farinha P, Molina TJ, Copie-Bergman C, Damotte D, **Salles GA**, Mottok A, Savage KJ, Scott DW, Traverse-Glehen A, Steidl C. Gene expression profiling of gray zone lymphoma. *Blood Adv*. 2020 Jun 9;4(11):2523-2535. doi: 10.1182/bloodadvances.2020001923. PMID: 32516416; PMCID: PMC7284085.
408. **Salles G**, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. *Lancet Oncol*. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5. PMID: 32511983.
409. Sarkozy C, Morschhauser F, Dubois S, Molina T, Michot JM, Cullières-Dartigues P, Suttle B, Karlin L, Le Gouill S, Picquenot JM, Dubois R, Tilly H, Herbaux C, Jardin F, **Salles G**, Ribrag V. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. *Clin Cancer Res*. 2020 Jul 1;26(13):3145-3153. doi: 10.1158/1078-0432.CCR-19-3741. Epub 2020 Mar 2. PMID: 32122924.
410. Delfau-Larue MH, Boulland ML, Beldi-Ferchiou A, Feugier P, Maisonneuve H, Casasnovas RO, Lemonnier F, Pica GM, Houot R, Ysebaert L, Tilly H, Eisenmann JC, Le Gouill S, Ribrag V, Godmer P, Glaisner S, Cartron G, Xerri L, **Salles GA**, Fest T, Morschhauser F. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. *Blood Adv*. 2020 Aug 11;4(14):3217-3223. doi: 10.1182/bloodadvances.2020001955. PMID: 32673385.
411. Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhompas A, Karlin L, Brisou G, Vercasson M, Hospital-Gustem C, Schwiertz V, Ranchon F, Rioufol C, Choquet M, Sujobert P, Ghergus D, Bouafia F, Golfier C, Lequeu H, Lazareth A, Novelli S, Devic P, Traverse Glehen A, Viel S, Venet F, Mialou V, Hequet O, Chauchet A, Arkam Y, Nicolas-Virelizier E, Peyrade F, Cavalieri D, Ader F, Ghesquières H, **Salles G**, Bachy E. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. *Am J Hematol*. 2020 Nov;95(11):1324-1333. doi: 10.1002/ajh.25951. Epub 2020 Aug 25. PMID: 32744738.
412. Michot JM, Bouabdallah R, Vitolo U, Doorduijn JK, **Salles G**, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, Chen T, Klein C, Hagner PR, Nikolova Z, Ribrag V. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. *Lancet Haematol*. 2020 Sep;7(9):e649-e659. doi: 10.1016/S2352-3026(20)30208-8. Epub 2020 Aug 3. PMID: 32758434.
413. Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, Cymbalista F; French Innovative Leukemia Organization (FILO). Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. *Leukemia*. 2020 Sep 15. doi: 10.1038/s41375-020-01009-z. Epub ahead of print. PMID: 32934355.

414. Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, Johnson NA, Larouche JF, Lugtenburg PJ, Patti C, **Salles GA**, Trneny M, de Vos S, Mir F, Samineni D, Kim SY, Jiang Y, Punnoose E, Sinha A, Clark E, Spielewoy N, Humphrey K, Bazeos A, Zelenetz AD. A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. *Blood*. 2020 Sep 21: blood.2020006578. doi: 10.1182/blood.2020006578. Epub ahead of print. PMID: 32959049.
415. Sarkozy C, Hung SS, Chavez EA, Duns G, Takata K, Chong LC, Aoki T, Jiang A, Miyata-Takata T, Telenius A, Slack GW, Molina TJ, Ben-Neriah S, Farinha P, Dartigues P, Damotte D, Mottok A, **Salles GA**, Casasnovas RO, Savage KJ, Laurent C, Scott DW, Traverse-Glehen A, Steidl C. Mutational Landscape of Grey Zone Lymphoma. *Blood*. 2020 Sep 22: blood.2020007507. doi: 10.1182/blood.2020007507. Epub ahead of print. PMID: 32961552.
416. Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL, Dickinson M, Jurczak W, Kazmierczak M, Opat S, Radford J, Schmitt A, Yang J, Whalen J, Agarwal S, Adib D, **Salles G**. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. *Lancet Oncol*. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6. PMID: 33035457.
417. Stilgenbauer S, Morschhauser F, Wendtner CM, Cartron G, Hallek M, Eichhorst B, Kozloff MF, Giever T, Lozanski G, Jiang Y, Huang H, Pignataro DS, Schary W, Humphrey K, Mobasher M, **Salles G**. Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). *Haematologica*. 2020 Oct 29; Online ahead of print:0. doi: 10.3324/haematol.2020.261107. PMID: 33121235.
418. Michallet AS, Letestu R, Le Garff-Tavernier M, Aanei CM, Ticchioni M, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, **Salles GA**, Tournilhac O, Delmer AJ, Portois C, Pegourie B, Leblond V, Tomowiak C, De Guibert S, Orsini Piocelle F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan-Graczyk M, Vilque JP, Aurrant T, Cymbalista F, Lepretre S, Levy V, Nguyen-Khac F, Feugier P. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. *Blood*. 2020 Nov 9: blood.2020008164. doi: 10.1182/blood.2020008164. Epub ahead of print. PMID: 33167024.
419. Périchou J, Ranchon F, Herledan C, Huot L, Larbre V, Carpentier I, Lazareth A, Karlin L, Beny K, Vantard N, Schwiertz V, Caffin AG, Baudouin A, Sesques P, Brisou G, Ghesquières H, **Salles G**, Rioufol C. Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARE and MEducation Toxicity) educational intervention on outpatients' knowledge to manage adverse effects. *PLoS One*. 2020 Dec 4;15(12):e0243309. doi: 10.1371/journal.pone.0243309. PMID: 33275634; PMCID: PMC7717911.
420. Barrientos JC, Hillmen P, **Salles G**, Sharman J, Stilgenbauer S, Gurtovaya O, Xing G, Ruzicka B, Bhargava P, Ghia P, Pagel JM. No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. *Leuk Lymphoma*. 2020 Dec 10:1-9. doi: 10.1080/10428194.2020.1845339. Epub ahead of print. PMID: 33297794.
421. Wagner-Johnston ND, Schuster SJ, deVos S, **Salles G**, Jurczak WJ, Flowers CR, Viardot A, Flinn IW, Martin P, Xing G, Rajakumaraswamy N, Gopal AK. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. *Leuk*

- Lymphoma. 2020 Dec 10:1-11. doi: 10.1080/10428194.2020.1855344. Epub ahead of print. PMID: 33300385.
422. Punnoose E, Peale FV, Szafer-Glusman E, Lei G, Bourgon R, Do AD, Kim E, Zhang L, Farinha P, Gascoyne RD, Munoz FJ, Martelli M, Mottok A, **Salles GA**, Sehn LH, Seymour JF, Trněný M, Oestergaard MZ, Mundt KE, Vitolo U. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. *Clin Lymphoma Myeloma Leuk.* 2020 Nov 10:S2152-2650(20)30628-5. doi: 10.1016/j.clml.2020.11.004. Epub ahead of print. PMID: 33303421.
423. Morschhauser F, Dyer MJS, Walter HS, Danilov AV, Ysebaert L, Hodson DJ, Fegan C, Rule SA, Radford J, Cartron G, Bouabdallah K, Davies AJ, Spurgeon S, Rajakumaraswamy N, Li B, Humeniuk R, Huang X, Bhargava P, Jürgensmeier JM, **Salles G**. Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. *Leukemia.* 2020 Dec 17. doi: 10.1038/s41375-020-01108-x. Epub ahead of print. PMID: 33328591. Oberic L, Peyrade F, Puyade M, Bonnet C, Dartigues-Cuillères P, Fabiani B, Ruminy P, Maisonneuve H, Abraham J, Thieblemont C, Feugier P, Salles G, Bijou F, Pica GM, Damaj G, Haioun C, Casasnovas RO, Farhat H, Le Calloch R, Waultier-Rascalou A, Malak S, Paget J, Gat E, Tilly H, Jardin F. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. *J Clin Oncol.* 2021 Jan 14:JCO2002666. doi: 10.1200/JCO.20.02666. Online ahead of print. PMID: 33444079
424. Bolen CR, Mattiello F, Herold M, Hiddemann W, Huet S, Klapper W, Marcus R, Mir F, **Salles GA**, Weigert O, Nielsen T, Oestergaard M, Venstrom J. Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. *Blood.* 2021 Jan 25:blood.2020008119. doi: 10.1182/blood.2020008119. Online ahead of print. nPMID: 33512481
425. Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illés Á, Johnson NA, Larouche JF, Lugtenburg PJ, Patti C, **Salles GA**, Trněný M, de Vos S, Mir F, Samineni D, Kim SY, Jiang Y, Punnoose E, Sinha A, Clark E, Spielewoy N, Humphrey K, Bazeos A, Zelenetz AD A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. *Blood.* 2021 Feb 4;137(5):600-609. doi: 10.1182/blood.2020006578. PMID: 33538797
426. Barba T, Bachy E, Maarek A, Fossard G, Genestier L, Anglicheau D, Moal V, Dantal J, Rieu P, Chemouny J, Charrier M, Durrbach A, Provot F, Ducloux D, Westeel PF, Heng AE, Rerolle JP, Barrou B, Grimbert P, Chatelet V, Mousson C, Janbon B, Pernin V, Frimat L, Cassuto E, Ouali N, Glotz D, Thierry A, Mariat C, Büchler M, Gaulard P, Leblond V, Morelon E, Dubois V, **Salles G**, Caillard S, Thaunat O. Characteristics of T and NK-cell Lymphomas After Renal Transplantation: a French National Multicentric Cohort Study. *Transplantation.* 2021 Feb 3. doi: 10.1097/TP.0000000000003568. Online ahead of print. PMID: 33560724
427. Ghesquières H, Rossi C, Cherblanc F, Le Guyader-Peyrou S, Bijou F, Sujobert P, Fabbro-Peray P, Bernier A, Belot A, Chartier L, Fornecker LM, Baldi I, Bouabdallah K, Laurent C, Oberic L, Morineau N, Le Gouill S, Morschhauser F, Haioun C, Damaj G, Guidez S, Labouré G, Fitoussi O, Lebras L, Gressin R, **Salles G**, Ysebaert L, Monnereau AA French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort. *BMC Public Health.* 2021 Mar 2;21(1):432. doi: 10.1186/s12889-021-10433-4. PMID: 33653294

428. Maurer MJ, Jakobsen LH, Mwangi R, Schmitz N, Farooq U, Flowers CR, de Nully Brown P, Thompson CA, Frederiksen H, Cunningham D, Jørgensen J, Poeschel V, Nowakowski G, Seymour JF, Merli F, Haioun C, Ghesquieres H, Ziepert M, Tilly H, **Salles G**, Shi Q, El-Galaly TC, Habermann TM. R/R International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. *Am J Hematol*. 2021 Mar 4. doi: 10.1002/ajh.26149. Online ahead of print.PMID: 33661547
429. Bekadja MA, Boumendil A, Blaise D, Chevallier P, Peggs KS, **Salles G**, Giebel S, Marks R, Arcese W, Milpied N, Finel H, Gorin NC. Cytotherapy. Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. 2021 Mar 4:S1465-3249(21)00007-4. doi: 10.1016/j.jcyt.2020.12.016. Online ahead of print.PMID: 33678598
430. Charra F, Philippe M, Herledan C, Caffin AG, Larbre V, Baudouin A, Schwiertz V, Vantard N, Labussiere-Wallet H, Ducastelle-Leprêtre S, Barraco F, Balsat M, Larcher MV, **Salles G**, Rioufol C, Ranchon F. Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program. *J Oncol Pharm Pract*. 2021 Mar 8:10781552211000115. doi: 10.1177/10781552211000115. Online ahead of print.PMID: 33683151

II - Reviews in Peer-reviewed journals

1. **Salles G**, Shipp MA, Coiffier B: Chemotherapy of non Hodgkin's aggressive lymphomas. *Semin Hematol* 1994, 31:46-69. <https://www.ncbi.nlm.nih.gov/pubmed/8122135>
2. Warzocha K, Bienvenu J, Coiffier B, **Salles G**: Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. *Eur. Cytokine Netw.*, 1995, 5:83-96. <https://www.ncbi.nlm.nih.gov/pubmed/7578992>
3. Warzocha K, **Salles G**. The tumor necrosis factor signaling complex: choosing a path toward cell death or cell proliferation. *Leukemia Lymphoma* 1998, 29:81-92 <https://www.ncbi.nlm.nih.gov/pubmed/9638978>
4. Coiffier B, Thieblemont C, Felman P, **Salles G**, Berger F. Indolent Nonfollicular Lymphomas : Characteristics, Treatment and Outcome. *Semin Hematol* 1999, 36:198-208 <https://www.ncbi.nlm.nih.gov/pubmed/10319388>
5. **Salles G**, Coiffier B. Autologous peripheral blood stem cell transplantation for Non-Hodgkin's lymphoma. *Baillieres Best Pract Res Clin Haematol*. 1999, 12:151-169 <https://www.ncbi.nlm.nih.gov/pubmed/11000990>
6. Thieblemont C, Felman P, Callet-Bauchu E, Traverse-Glehen A, **Salles G**, Berger F, Coiffier B. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. *Lancet Oncol* 2003; 4:95-103. PMID: 12573351

7. Berger F, Traverse-Glehen A, Felman P, Callet-Bauchu E, Thieblemont C, Ffrench M, Magaud J-P, **Salles G**, Coiffier B. Clinicopathological features of Waldenström's Macroglobulinemia and Marginal Zone Lymphoma: Are they distinct or do they represent a unique entity? *Clinical Lymphoma* 2005; 5:220-4. PMID: 15794852
8. Lech-Maranda E, Baseggio L, Charlot C, Rigal D, Berger F, Jamroziak K, Warzocha K, Coiffier B, **Salles G**. Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. *Leuk Lymphoma* 2007; 48:2235-8. PMID: 17990180
9. **Salles GA**. Clinical features, prognosis and treatment of follicular lymphoma. *Hematology Am Soc Hematol Educ Program* 2007; 216-25. PMID: 18024633
10. Johnston A, **Salles G**. Prognostic systems for lymphomas. *Hematol Oncol Clin North Am*. 2008; 22:839-61. PMID: 18954740
11. Rachinel N, **Salles G**. The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate. *Curr Hematol Malig Rep*. 2009; 4:196-201. PMID: 20425408
12. Bachy E, **Salles G**. Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. *Best Pract Res Clin Haematol*. 2011; 24:257-70. PMID: 21658622
13. Michallet AS, Coiffier B, **Salles G**. Maintenance therapy in follicular lymphoma. *Curr Opin Oncol*. 2011; 23:449-54. PMID: 21734580
14. Traverse-Glehen A, Baseggio L, **Salles G**, Felman P, Berger F. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification. *Curr Opin Oncol*. 2011; 23:441-8. PMID: 21760505
15. Roulland S, Faroudi M, Mamessier E, Sungalee S, **Salles G**, Nadel B. Early steps of follicular lymphoma pathogenesis. *Adv Immunol*. 2011; 111:1-46 PMID: 21970951
16. Bertoni F, Coiffier B, **Salles G**, Stathis A, Traverse-Glehen A, Thieblemont C, Zucca E. MALT lymphomas: pathogenesis can drive treatment. *Oncology (Williston Park)*. 2011; 25(12):1134-42, 1147 PMID: 22229204
17. Dreyling M, Ghielmini M, Marcus R, **Salles G**, Vitolo U; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2011; Suppl 6:vi59-63. PMID: 21908506
18. **Salles G**, Ghesquières H, Bachy E. What is the best first-line treatment strategy for patients with indolent lymphomas? *Am Soc Clin Oncol Educ Book*. 2012; 488-93. PMID: 24451785
19. Traverse-Glehen A, Bertoni F, Thieblemont C, Zucca E, Coiffier B, Berger F, **Salles G**. Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma. *Oncology (Williston Park)* 2012; 16(1):92-9, 103-4. PMID: 22393802
20. Thieblemont C, Davi F, Noguera ME, Brière J, Bertoni F, Zucca E, Traverse-Glehen A, Felman P, Berger F, **Salles G**, Coiffier B. Splenic marginal zone lymphoma: current knowledge and future directions. *Oncology (Williston Park)*. 2012; 26(2):194-202 PMID: 22489356
21. Traverse-Glehen A, Baseggio L, **Salles G**, Coiffier B, Felman P, Berger F. Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. *Discov Med*. 2012; 13(71):253-65. PMID: 22541613
22. **Salles G**, Ghesquières H. Current and future management of follicular lymphoma. *Int J Hematol*. 2012; 96(5):544-51 PMID: 23108535

23. Sarkozy C, **Salles G**. Treatment approaches to asymptomatic follicular lymphoma. *Expert Rev Hematol*. 2013; 6(6):747-58 PMID: 24219551
24. Viel S, Charrier E, Marçais A, Rouzair P, Bienvenu J, Karlin L, **Salles G**, Walzer T. Monitoring NK cell activity in patients with hematological malignancies. *Oncoimmunology* 2013; 2(9):e26011. PMID: 24327939
25. Dreyling M, Ghielmini M, Marcus R, **Salles G**, Vitolo U, Ladetto M; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014; 25Suppl 3:iii76-iii82. PMID: 25122695
26. Bachy E, **Salles G**. Are we nearing an era of chemotherapy-free management of indolent lymphoma? *Clin Cancer Res* 2014; 20(20):5226-39. PMID: 25320372
27. Sarkozy C, Camus V, Tilly H, **Salles G**, Jardin F. Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era. *Leuk Lymphoma* 2014; 3:1-29 PMID: 25363401
28. Sarkozy C, **Salles G**, Bachy E. Chemotherapy-free treatment in patients with follicular lymphoma. *Expert Rev Hematol*. 2015; 13:1-17. PMID: 25585961
29. Rioufol C, **Salles G**. Obinutuzumab for chronic lymphocytic leukemia. *Expert Rev Hematol*. 2014; 7(5):533-43. PMID: 25163491
30. Bachy E, **Salles G**. Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma. *Semin Hematol*. 2015; 52(2):107-18. PMID: 25805590
31. Sarkozy C, **Salles G**, Falandry C. The biology of aging and lymphoma: a complex interplay. *Curr Oncol Rep*. 2015;17(7):32. PMID: 26003736
32. Rioufol C, **Salles G**. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. *Expert Rev Anticancer Ther*. 2015; 30:1-10. PMID: 25818308
33. Illidge T, Klein C, Sehn LH, Davies A, **Salles G**, Cartron G. Obinutuzumab in hematologic malignancies: Lessons learned to date. *Cancer Treat Rev*. 2015; 14. pii: S0305-7372(15)00148-6. PMID: 26190254
34. Lepretre S, Dartigeas C, Feugier P, Marty M, **Salles G**. Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies. *Leuk Lymphoma*. 2015; 8:1-14. PMID: 26308278
35. Sujobert P, Rioufol C, **Salles GA**. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma. *Cancer J*. 2016; 22(1):12-6. PMID: 26841011
36. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, **Salles G**, Schuringa JJ; other authors of the EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. *Haematologica*. 2016; 101(2):115-208. PMID: 26819058

37. Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D. Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. *Oncoimmunology*. 2016; 19;5(7):e1186323. PMID: 27622041
38. Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M; ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017; 28(12):3109. PMID: 28327933
39. Sujobert P, **Salles G**, Bachy E. Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant? *Hematol Oncol Clin North Am*. 2016; 30(6):1163-1177. PMID: 27888873
40. Grange B, Callet-Bauchu E, **Salles G**, Sujobert P. Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas. *Expert Rev Mol Diagn*. 2017; 17(6):623-632. PMID: 28480776
41. **Salles G**, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG. Rituximab in B- Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. *Adv Ther*. 2017; 34(10):2232-2273. PMID: 28983798
42. Huet S, Sujobert P, **Salles G**. From genetics to the clinic: a translational perspective on follicular lymphoma. *Nat Rev Cancer*. 2018; 18(4):224-239. PMID: 29422597
43. Guillermin Y, Lopez J, Chabane K, Hayette S, Bardel C, **Salles G**, Sujobert P, Huet S. What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies. *Int J Mol Sci*. 2018; 19(4). PMID: 29677173
44. **Salles GA**, Pettengell R, Cordoba R, Długosz-Danecka M, Jurczak W, Tilly H. Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. *Leuk Lymphoma*. 2019; 31:1-16. PMID: 30702000
45. Hübel K, **Salles G**, Marcus R, Zinzani PL, Dreyling M. New Treatment Options in Advanced Stage Follicular Lymphoma. *Hemasphere*. 2018; 2(6):e156. PMID: 31723794
46. Sujobert P, Le Bris Y, de Leval L, Gros A, Merlio JP, Pastoret C, Huet S, Sarkozy C, Davi F, Callanan M, Thieblemont C, Sibon D, Asnafi V, Preudhomme C, Gaulard P, Jardin F, **Salles G**, Macintyre E. The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies. *Hemasphere*. 2018; 3(1):e169. PMID: 31723808
47. **Salles G**. New drugs for old targets. *Hematol Oncol*. 2019 37 Suppl 1:101-104. [PMID: 31187537](#)
48. Huet S, **Salles G**. Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma. *JCO Oncol Pract*. 2020; 16(9):561-568. PMID: 32421389
49. Bourbon E, **Salles G**. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. *Expert Opin Investig Drugs*. 2020; 29(10):1079-1088. PMID: 32700972.

50. **Salles G.** How do I sequence therapy for follicular lymphoma? Hematology Am Soc Hematol Educ Program. 2020(1):287-294. PMID: 33275688 Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
51. Dreyling M, Ghielmini M, Rule S, **Salles G**, Ladetto M, Tonino SH, Herfarth K, Seymour JF, Jerkeman M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Mar;32(3):298-308. doi: 10.1016/j.annonc.2020.11.008. Epub 2020 Nov 26. PMID: 33249059
52. Sehn LH & **Salles G.** Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 2021; 384(9):842-858. doi: 10.1056/NEJMra2027612. PMID: 33657296

III - Editorials, correspondence or invited papers in peer-reviewed journals

1. Coiffier B, **Salles G.** Does surgery belong to medical history for gastric lymphomas? Ann Oncol. 1997 May;8(5):419-21. <https://www.ncbi.nlm.nih.gov/pubmed/9233518>
2. **Salles G.** Towards new prognostic factors in diffuse large cell non-Hodkin's lymphoma. Ann Oncol 1996, 7 : 993-996. <https://www.ncbi.nlm.nih.gov/pubmed/9037355>
3. **Salles G**, Coiffier B. Histologic transformation in follicular lymphoma. Ann Oncol 1998, 9 : 803-805. <https://www.ncbi.nlm.nih.gov/pubmed/9789600>
4. Coiffier B, **Salles G.** Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma. Blood 2004, 104:1584-6. <https://www.ncbi.nlm.nih.gov/pubmed/15317734>
5. **Salles G** and Coiffier B. Inherited cytokine response and risk of lymphoma. Lancet Oncol 2006, 7:3-4. <https://www.ncbi.nlm.nih.gov/pubmed/16389173>
6. Hagenbeek A, Gascoyne RD, Dreyling M, Kluin P, Engert A, **Salles G.** Biomarkers and prognosis in malignant lymphomas. Clin Lymphoma Myeloma. 2009; 9:160-6 <https://www.ncbi.nlm.nih.gov/pubmed/19406728>
7. Traverse-Glehen A, Baseggio L, Callet-Bauchu E, Ffrench M, Coiffier B, **Salles G**, Felman P, Berger F. Hairy cell leukaemia-variant and splenic red pulp lymphoma: a single entity? Br J Haematol. 2010 150:113-6. <https://www.ncbi.nlm.nih.gov/pubmed/20230408>
8. **Salles G.** Is there a role for bortezomib combinations in the management of follicular lymphoma patients? J Clin Oncol 2011 29:3349-50 <https://www.ncbi.nlm.nih.gov/pubmed/21810690>
9. Walter HS, **Salles GA**, Dyer MJ. New Agents to Treat Chronic Lymphocytic Leukemia. N Engl J Med. 2016 ;374(22):2185-6. <https://www.ncbi.nlm.nih.gov/pubmed/27248633>
10. Meignan M, Cottreau AS, Versari A, Chartier L, Dupuis J, Boussetta S, Grassi I, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, **Salles G**, Luminari S, Trotman J. Reply to H.J.A. Adams et al and E. Laffon et al. J Clin Oncol. 2017 10;35(8):920-923. <https://www.ncbi.nlm.nih.gov/pubmed/28029310>
11. Tilly H, **Salles G**, Molina TJ, Casasnovas RO, Morschhauser F, Coiffier B. Through the Glass Ceiling. J Clin Oncol. 2018 ;36(9):923. <https://www.ncbi.nlm.nih.gov/pubmed/29369698>
12. Bachy E, **Salles G.** Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma.

J Oncol Pract. 2019 Mar;15(3):147-148. <https://www.ncbi.nlm.nih.gov/pubmed/30861363>

13. **Salles G**. New drugs for old targets. Hematol Oncol. 2019 37 Suppl 1:101-104. <https://www.ncbi.nlm.nih.gov/pubmed/31187537>
14. Huet S, **Salles G**. Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma. JCO Oncol Pract. 2020 May 18;JOP1900691. doi: 10.1200/JOP.19.00691. Epub ahead of print. PMID: 32421389.
15. Ghesquieres H, **Salles G**. Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting. J Clin Oncol. 2020 Jul 15;JCO2001134. doi: 10.1200/JCO.20.01134. Epub ahead of print. PMID: 32667832.

IV- Books

Editors: Lenz, Georg, **Salles, Gilles** (Eds.). Aggressive Lymphomas. 2019. VII, 360.
Publisher: Springer International Publishing
Hardcover ISBN: 978-3-030-00361-6

V – Book Chapters

1. **Salles G**, Coiffier B: Treatment of non Hodgkin's diffuse large cell lymphomas, in G. A. Pangalis (Ed): Malignant lymphomas : biology and treatment. An update. Springer Verlag, Berlin, 1995, pp 127-141.
2. Coiffier B, **Salles G**, Bastion Y: Prognostic factors in non Hodgkin's lymphoma, in I. T. Magrath (eds) : The Non Hodgkin's Lymphomas. London, Adward Arnold Ltd, 1997, pp739-768
3. B Coiffier et **Salles G**. High Dose chemotherapy in aggressive lymphomas. In High dose Chemotherapy, principles and practice. P Lorigan and E Vandenberghe. Martin Dunitz Ltd London 2002, pp127-141.
4. Berger F, Traverse-Glehen A, **Salles G**. Nodal marginal zone B-cell lymphoma. In Non-Hodgkin's lymphoma. Mauch P, Armitage J, Coiffier B, Dalla-Favera R, Harris N. Lippincott Willimams & Wilkins Editors, 2004. pp361-364